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Abstract 
Background. American Indians experience higher stroke morbidity and mortality 
compared to US general population, but are underrepresented in public health research. 
Data on incident stroke in American Indians derive mainly from the Strong Heart Study 
(SHS), a population-based cohort study of cardiovascular disease in 4549 American 
Indians who were 45-74 years old when baseline exams were conducted from 1988-1990. 
The SHS had higher stroke rates than reported for Whites and African Americans in 
external comparisons to other cohorts. These findings suggested similar disparities in 
covert vascular brain injury (VBI), an often asymptomatic form of cerebrovascular 
disease that precedes clinical events. Accordingly, from 2010-2013 the Strong Heart 
Stroke Study (SHSS) used structural cranial magnetic resonance imaging to assess covert 
VBI in 1033 surviving members of the SHS.  
Goals. In this dissertation we addressed three limitations to using SHS and SHSS 
data for analysis of stroke and covert VBI in American Indians: Manuscript 1) lack of 
research that directly compares stroke incidence and mortality in American Indians vs. 
other racial groups, and which limits current knowledge to external comparisons that do 
not account for differences in stroke risk factors; Manuscript 2) potential selection bias in 
SHSS data when survival and participation of cohort members depends on both the 
exposures and outcomes of interest; and Manuscript 3) an inherent limitation in effect 
measures estimates that condition on categories defined by progressively older age or 
longer time since exposure, and which leads to observed point estimates that are 
potentially biased estimates of the true effects. 
Manuscript 1. Methods: We pooled data from the SHS and the Atherosclerosis 
Risk in Communities Study (ARIC) to compare stroke risk and post-stroke mortality in 
American Indians vs. Blacks and Whites. We used Cox regression to estimate hazard 
ratios (HR) with attained age as the time scale to account for differences in baseline age 
at enrollment, and adjusted estimates for baseline factors that included prevalent 
hypertension and diabetes. Due to effect modification, analyses were stratified by birth 
year tertile (1914-1930, 1931-1937, and 1938-1947). We used logistic regression to 
compare 30-day and 1-year post-stroke mortality among participants from both studies 
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who experienced stroke during follow-up. Results: Stroke risk among American Indians 
in the SHS was lower than among Blacks for all birth year tertiles (1914-1930: HR = 0.9 
(95% CI = 0.7, 1.1); 1931-1937: HR = 0.9 (95% CI = 0.7, 1.2); 1938-1947: HR = 0.9 
(95% CI = 0.7, 1.2)), but higher than among Whites (1914-1930: HR = 1.6 (95% CI = 
1.3, 2.0); 1931-1937: HR = 2.2 (95% CI = 1.7, 2.8); 1938-1947: HR = 2.7 (95% CI = 2.0, 
3.6)) in ARIC. Adjusting for risk factors including prevalent diabetes at baseline resulted 
in strengthening of associations compared to Blacks (oldest to youngest tertile HR = 0.8 
(95% CI = 0.6-1.0); 0.7 (95% CI = 0.5-1.0); and 0.6 (95% CI = 0.4-0.8)), and attenuation 
of associations compared to Whites (oldest to youngest tertile HR = 1.1 (95% CI = 0.9-
1.5); 1.2 (95% CI = 0.9-1.6); and 1.1 (95% CI = 0.8-1.5)). American Indians had higher 
risk of 30-day and 1-year mortality compared to Blacks (relative risk = 2.2 (95% CI = 
1.4-3.0) and 1.4 (95% CI = 1.1-1.8), respectively) and Whites (relative risk = 1.8 (95% 
CI = 1.2-2.3) and 1.5 (95% CI = 1.1-1.8), respectively). These comparisons persisted 
after adjusting for risk factors. 
Manuscript 2. Methods: We used marginal structural models with inverse 
probability weighting to adjust for selection bias in the SHSS, applied to the analysis of 
prevalent hypertension and covert VBI as measured by white matter hyperintensities. 
Predicted probabilities of survival from 1988-2010 and participation of survivors were 
estimated and inverted to create weights, and stabilized using conventional methods to 
reflect the distribution of hypertension in cohort participants. In addition, we computed 
novel stabilized weights that account for each person’s probability of meeting the 
inclusion criterion of remaining stroke-free up to their SHSS exam. These weights 
allowed us to avoid over-correcting for attrition of individuals who would have 
subsequently gone on to experience clinical stroke. We applied these weights to estimate 
the prevalence difference (PD) for the association of hypertension with a binary indicator 
of abnormal VBI, as well as the mean difference (MD) for a continuous variable 
reflecting the ratio of white matter/total intracranial volume; the ratio estimates were 
multiplied by 1000 to simplify presentation of results. Hypertension was evaluated as 
both a cross-sectional risk factor and accounting for longitudinal trends in prevalence 
since baseline. Results: In the cross-sectional analysis, hypertension was associated with 
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higher prevalence of abnormal VBI in unweighted models (PD = 7.9% (95% CI = -2, 
17)). The point estimate increased 13% after selection weighting (PD = 8.9% (95% CI = 
0, 18)). Prevalent hypertension was likewise associated with a higher proportion of white 
matter volume compared to the total intracranial volume in unweighted models (MD = 
0.8 (95% CI = -0.4, 2.0)) and after selection weighting (MD = 0.9 (95% CI = -0.3, 2.1)). 
Adjusting weights to account for the stroke-free inclusion criterion did not change results 
compared to the conventional stabilized estimates. In the analysis treating hypertension as 
a longitudinal exposure, prevalent hypertension at all three study exams was associated 
with higher prevalence of abnormal VBI (PD = 8.0% (95% CI = -6, 22)) and higher ratio 
of white matter/total intracranial volume (MD = 1.7 (95% CI = 0.0, 3.4)) compared to not 
having hypertension at any exam. Selection weighting had no appreciable impact on 
point estimates in the longitudinal analysis. 
Manuscript 3. Methods: We used Mathematica software with constrained 
optimization to identify bounds for the risk difference (RD) when conditioning on event-
free survival to some minimum age or time since exposure. Bounds were identified 
assuming only causative exposure effects in the target population, and allowing for 
exposure to prevent disease in some individuals so long as the causative effects were 
proportionally greater in the overall population. We applied these bounds to the analysis 
of post-stroke survival from Manuscript 1, with follow-up time divided into 0-30 days, 
31-180 days, and 181-365 days after the stroke event. Results: The RD attenuated across 
follow-up periods for American Indians vs. Blacks (0-30 days: RD = 14% (95% CI = 6, 
23); 31-180 days: RD = -1% (95% CI = -7, 4); 181-365 days: RD = -3% (95% CI = -7, 
2)) and Whites (0-30 days: RD = 12% (95% CI = 3, 21); 31-180 days: RD = 1% (95% CI 
= -5, 6); 181-365 days: RD = -2% (95% CI = -6, 3)). With assumptions of only causative 
exposure effects, bounds on the the conditional risk difference for American Indians vs. 
Blacks were 0-16% for 0-30 days post-stroke event, and 1-13% for 181-365 days post-
stroke. For American Indians vs. Whites the bounds were 0-14% for 0-30 days post 
stroke, and 0-13% for 31-180 days post-stroke. Allowing for preventive effects that were 
equal to or less than causative effects yielded bounds that were too wide for meaningful 
interpretation (all lower bounds = 0; all upper bounds ≥ 30).  
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Conclusions. We found that American Indians in the SHS had lower stroke risk 
than Blacks, but not than Whites, in ARIC after adjusting for risk factors that included 
prevalent diabetes. These findings suggest that diabetes may be a factor behind stroke 
disparities in some American Indian communities. American Indians had higher post-
stroke mortality than Blacks and Whites especially in the first 30 days after stroke onset, 
but cumulative risk comparisons and analyses using bounds for conditional effects were 
consistent with elevated risk persisting for at least 1 year. Among long-term survivors of 
the SHS who participated in the SHSS assessment of covert VBI, selection bias may be 
of concern for some analyses. Although adjusting selection weights for the stroke-free 
inclusion criterion did not change results in this example, other studies with inclusion 
criteria that result in excluding larger proportions of the study population may wish to 
include sensitivity analyses with similar adjustments. 
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A.  Introduction 
American Indians experience substantial stroke morbidity and mortality but are 
underrepresented in research on stroke and covert vascular brain injury (VBI), such as 
white matter hyperintensities (WMH) or silent infarcts that often precede clinical events. 
Data on incident stroke in American Indians derive mainly from the Strong Heart Study 
(SHS), a population-based cohort study of cardiovascular disease in 4549 American 
Indians from three geographic regions who were 45-74 years old at baseline.1 From 1988-
2004 the SHS documented stroke rates in men and women exceeding those for Whites 
and Blacks in other large cohort studies.2 Thirty-day and 1-year mortality were also 
unexpectedly high among SHS participants who experienced incident stroke, though it 
was unclear whether this finding was driven primarily by disparities in short-term risks 
that attenuated among longer term survivors. No longitudinal cohorts exist that allow 
direct comparison of stroke incidence or post-stroke survival in American Indians with 
other racial groups.  
The Atherosclerosis Risk in Communities (ARIC) Study is a prospective cohort 
study that enrolled 15,792 participants from four locations across the US.3 Recruitment 
and baseline exams were conducted from 1987-1989, with cardiovascular events and 
stroke ascertained through 2011. Analyses documented higher risk in Black participants 
than in Whites,4 and ARIC was among the cohorts to which SHS investigators made 
external comparison of stroke rates for American Indians. ARIC and the SHS shared 
many similarities in study design and timing of enrollment for baseline exams, and 
together represent an opportunity for pooling data to include American Indians in racial 
comparisons of stroke incidence and survival. 
High stroke incidence observed in SHS participants suggests similarly elevated 
burdens of covert VBI. Accordingly, from 2010-2013 the ancillary Strong Heart Stroke 
Study (SHSS) used cranial magnetic resonance imaging to investigate covert VBI and its 
risk factors in 1033 SHS members. Because the SHSS comprised long-term survivors of 
the SHS cohort, selection bias could arise from differential mortality or attrition 
associated with the exposures and outcomes of interest.5 In this context, selection bias 
would likely result in underestimating magnitudes of associations between risk factors 
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and covert VBI, and analyses to address the SHSS scientific aims may need to adjust for 
potential selection bias in the data. 
The SHSS analytic plan includes estimating effect measures for the cohort as a 
whole, and separately by age category (65-74, 75-84, and ≥ 85 years old). Age-specific 
estimates can suffer from a special form of selection bias that renders effects 
fundamentally unidentifiable, which means they cannot be directly estimated from 
observed data.6 This type of selection bias also applies to effect estimates that condition 
on surviving some minimum time since start of treatment or exposure, such as 1-year 
survival among people who survive at least 30 days after their stroke event. In older age 
groups or longer-term survivors this “conditional effects bias” can lead to observing 
effect estimates that are diminished or even qualitatively reversed compared to the true 
associations. In randomized controlled trials cumulative effects are estimated without 
bias, in expectation, but no methods currently exist that guarantee unbiased estimation of 
conditional effects even for prospective studies with perfect randomization, large sample 
size, and no missing data or attrition. For scientific questions that necessitate estimating 
conditional effects measures, methods to place bounds around unobservable parameters 
would facilitate sensitivity analyses and contextualize interpretation of results. 
This dissertation comprises three papers that address the questions described above. 
In Manuscript 1: Comparing stroke incidence and survival in American Indians, Blacks, 
and Whites: the Strong Heart Study and Atherosclerosis Risk in Communities Study, we 
pooled longitudinal data from the SHS and ARIC to evaluate racial differences in stroke 
outcomes with and without adjusting for stroke risk factors. Manuscript 1 expands on 
previous findings in the SHS, and is the first population-based longitudinal analysis to 
directly compare stroke incidence and survival in American Indians to any other racial 
group.  
In Manuscript 2: Inverse probability weighting for selection bias tailored to 
inclusion criteria in the target population: covert vascular brain injury among American 
Indians in the Strong Heart Stroke Study, we used marginal structural models with 
inverse probability weighting (IPW) to adjust for selection bias in the analysis of 
prevalent hypertension and covert VBI in the SHSS. Manuscript 2 extends traditional 
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applications of IPW for selection bias to account for correlation between equations used 
to predict selection and the probability of meeting inclusion criteria, in this case absence 
of prevalent stroke.  
In Manuscript 3: A bounding method to for effect estimates conditioned on age or 
time since exposure, we expanded on a previous publication6 to develop a simple 
bounding method for conditional effects based on identifiable parameters that can be 
estimated from observed data. Manuscript 3 provides a practical tool that can be applied 
to conditional effects in analyses using SHS and SHSS data, and which can be more 
broadly applied to other longitudinal or cross-sectional studies that are focused on 
quantifying effects conditioned on age or time. 
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B.  Background 
B.1 Stroke 
Stroke is the general term used to describe clinical symptoms resulting from 
restriction of blood flow to (ischemic stroke) or bleeding from (hemorrhagic stroke) 
blood vessels in the brain.7 Stroke is strongly associated with older age and biological or 
vascular aging, especially in developed countries but also increasingly in the developing 
world.8,9 A conventional, albeit arbitrary, diagnostic criterion requires symptom duration 
of at least 24 hours to distinguish stroke from transient ischemic attack.10 In recent years 
some researchers and clinicians have advocated for the term “brain attack” to reflect 
mechanistic similarities between ischemic stroke and heart attack, and to emphasize the 
need for acute emergency treatment as soon as possible after symptom onset, though this 
terminology is criticized for insufficient focus on post-stroke disability and 
rehabilitation.11,12 Stroke has also been called a “cerebrovascular accident,” although this 
terminology has been criticized as implying chance events that are not preventable.  
Vascular aging and stroke are caused by deterioration in the health and functioning 
of vascular endothelial cells that line the walls of blood vessels.13 Oxidative stress and 
inflammation contribute to this vascular endothelial dysfunction,14 which in turn 
contributes to atherosclerosis and increased risk of ischemic and hemorrhagic strokes via 
plaque formation, plaque rupture, and weakened blood vessels.15-19 Relative burdens of 
stroke subtypes vary between countries.20 In the US about 85% of strokes are ischemic, 
and 15% are hemorrhagic.7 The US also exhibits geographical variation in stroke risk, 
with the highest burdens found among residents of the “stroke belt” across the 
Southeastern states.21 
There are three main causes of ischemic stroke. Cerebrovascular blood flow can be 
restricted by clots that form in the brain, clots that travel to the brain from other parts of 
the body, or narrowing of the blood vessels.22 About 30% of strokes are cryptogenic, with 
unknown cause.23 Normal cerebrovascular blood flow in the cortex is approximately 50 
ml/100 mg/minute, but reduction by as much as 60% can occur without causing 
noticeable symptoms.11 Blockage that reduces blood flow below 10 mL/100 mg/minute 
causes rapid membrane failure and cell death in an area of affected tissue known as the 
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infarct core. The core is surrounded by a region of less obstructed blood flow in which 
neuronal function is impaired but the cells are still intact. This region, known as the 
ischemic penumbra, is the target for acute thrombolytic treatment and subsequent 
rehabilitation therapy.24 In general, treatment within 3 hours of symptom onset is 
essential for restoring full or partial function to the penumbra. Approximately one-fourth 
of ischemic stroke victims die within one year of the event.25 
Hemorrhagic stroke occurs when blood leaks from weakened or damaged blood 
vessels in the brain. Intracerebral hemorrhage occurs when a diseased blood vessel leaks 
or bursts within the brain, and accounts for about two-thirds of hemorrhagic stroke.26 The 
remaining one-third reflect sub-arachnoid hemorrhage, which is bleeding between the 
layers of tissue that cover the brain and is usually caused by aneurism rupture or physical 
trauma. Depending on the location and extent of the lesion, hemorrhagic stroke can result 
in cell death due to oxygen deprivation downstream from the bleeding, as well as damage 
to surrounding tissue from the extravascular hematoma. Hemorrhagic stroke can occur in 
the absence of previous ischemia, or as the so-called “hemorrhagic transformation,” in 
which bleeding occurs at the site of a primary ischemic stroke.27 Hemorrhagic stroke is 
more lethal than ischemic stroke; about half of all victims die within one year of the 
event.28 
Risk factors for stroke are similar to risk factors for other cardiovascular diseases. 
In general, risk factors can be subdivided into modifiable and unmodifiable categories, 
with both informing general assessment of an individual’s risk profile while the latter can 
also serve as targets for preventive intervention.25 Unmodifiable risk factors include older 
age; male sex, although females have higher risk for some age categories; Black, 
American Indian, or Hispanic race/ethnicity; genetic predisposition; and low birth weight, 
although this may be considered modifiable from a primordial prevention perspective.29 
Major modifiable risk factors include high blood pressure; diabetes; cardiac arrhythmias, 
especially atrial fibrillation; left ventricular hypertrophy; dyslipidemia; smoking; physical 
inactivity; depression; and obesity.25,30-33 Current understanding of stroke risk factors has 
been largely shaped by US-based cohort studies, including ARIC.34-41 Unfortunately, the 
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prevalence of many risk factors is increasing, with ominous implications for public 
health.42,43 
For decades stroke was the 3rd leading cause of death in the US after heart disease 
and cancer, but in the last few years it has dropped to 4th, after chronic lower respiratory 
disease.44 This change is generally attributed to improved management of chronic disease 
risk factors, most notably hypertension and atrial fibrillation,45 although the decreased 
mortality could be due in part to improved specificity of stroke diagnosis.46 Most strokes 
occur in middle-aged and elderly adults, thus most clinical and epidemiologic research 
has focused on this population. In recent years the decline in stroke mortality has 
plateaued,47,48 however, and evidence increasingly suggests rising stroke incidence 
among people younger than 45 years old and in some racial minority populations.49-52 
B.2 Racial Disparities 
Stroke incidence and survival varies by race and ethnicity. According to the Centers 
for Disease Control and Prevention, in 2013 stroke prevalence was higher in people 
reporting American Indian (4.6%) or Black (4.0%) race than in people identifying as 
White (2.5%).7 Black stroke survivors also report more disability than their White 
counterparts, such as difficulty walking 10 steps without resting (42% vs. 29%), using 
fingers to grasp small objects (18% vs. 11%), or participating in social activities (24% vs. 
16%).53 People of color die from stroke at younger ages than Whites,54 and Blacks who 
experience stroke have higher mortality rates than Whites.55-57 Not surprisingly, research 
suggests that disparities in stroke incidence are linked to disproportionate burdens of 
stroke risk factors, though most research has focused on Blacks and the vast majority of 
publications do not include American Indians or Alaska Natives.58-64 Among stroke 
survivors, Blacks and Hispanics report poorer health-related quality of life and more 
stroke-related disability than Whites.65,66  
Several large cohort studies have directly compared stroke incidence in Black and 
White participants. In ARIC from 1987-1995 stroke rates were higher in Black men (53 
per 10,000 person-years (95% CI = 41, 69)) and women (40 per 10,000 person-years 
(95% CI = 31, 51)) than in White men (20 per 10,000 person-years (95% CI = 16, 26)) 
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and women (15 per 10,000 person-years (95% CI = 12, 19)).4 Thirty-day case fatality 
rates were also higher among Black than White stroke victims (13% vs. 9%), although 
the smaller number of fatalities did not allow for precise point estimates. In the 
Cardiovascular Health Study, Black women had higher 5- and 10-year stroke rates (15.7 
and 16.3 per 10,000 person years, respectively) than White men (15.4 and 15.2, 
respectively) or women (9.7 and 13.2, respectively), but interpretation of rates for Blacks 
of both sexes is limited due to relatively small numbers of events.34 Of 390 
Cardiovascular Health Study participants who experienced incident stroke from 1989-
1997, fatalities were 2.9 times higher in Blacks than in Whites.67 
B.3 Covert Vascular Brain Injury 
Covert VBI typically precedes clinical events, manifesting as WMH, hemorrhages, 
infarcts, or atrophy in the absence of stroke. These conditions have been linked to 
behavioral changes, cognitive impairment, dementia, and subsequent stroke and death.68-
72 Small vessel disease is implicated in the etiology of covert VBI,73 as are older age, 
hypertension, and diabetes.74-77 Large cohort studies, including ARIC, that used magnetic 
resonance imaging to quantify covert VBI documented high prevalence of brain 
abnormalities in middle-aged and elderly populations without a history of stroke or 
transient ischemic attack.78-80 Data also suggest that defining cerebrovascular disease 
only by clinical symptoms of transient ischemic attack or stroke dramatically 
underestimates the burden of covert disease.81  
B.4 Stroke in American Indians 
American Indians and Alaska Natives comprise 1.7% of the US population (5.2 
million people),82 and approximately 45% live on rural reservations. Until recently it was 
widely believed that American Indians experienced less stroke-related morbidity and 
mortality than the general population,83 despite disproportionate burdens from many 
chronic diseases and other stroke risk factors, including hypertension, obesity, type 2 
diabetes and cardiovascular disease.84 In an analysis of longitudinal changes 4 years after 
enrollment, the SHS reported unfavorable results for hypertension, blood lipids, diabetes, 
and albuminuria.85 Even among modifiable risk factors that did not show longitudinal 
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differences, the SHS cohort still exhibited disproportionate levels of low physical 
activity, obesity, and smoking compared to the general population. The Indian Health 
Service states that American Indians and Alaska Natives in their service population are 
60% more likely than Whites to experience a stroke, and self-reported stroke is higher for 
American Indians and Alaska Natives than other US racial groups.44 American Indians 
have been excluded or underrepresented from the vast majority of stroke research, 
however, and a 2011 statement from the American Heart Association/American Stroke 
Association concluded that stroke among Native people has not been thoroughly 
examined.52 
The only rigorous data on stroke incidence and mortality in American Indians 
comes from the SHS. Using meticulous community surveillance, 306 strokes were 
prospectively ascertained from 1989-2004 among 4549 participants. In the seminal 
publication on stroke incidence in American Indians, age-adjusted rates in the SHS were 
71 and 65 per 10,000 person-years for men and women, respectively, with 7% cumulative 
incidence from 1988-2004.2 No direct racial comparisons were possible, but the SHS 
incidence rates were higher than for Blacks or Whites of similar ages in the Framingham 
Heart Study,36 Cardiovascular Health Study,34 and ARIC.4 Age-specific incidence rates 
were also consistently higher in the SHS cohort than age-matched rates in Whites from 
Rochester, Minnesota from 1985-198986 and in Blacks in the Greater Cincinnati/Northern 
Kentucky Stroke Study in 1993.87 Stroke mortality in American Indians has been 
reported as being both lower54 and higher55 than Whites. These inconsistencies may in 
part reflect data quality issues, including underestimation of disease due to racial 
misclassification.88,89 Among American Indians in the SHS who experienced stroke, 1-
year case-fatality was 31% for men and 33% for women, compared to 21% for men and 
24% for women in pooled data from multiple cohorts.2 Similarly, in Montana from 1991-
2000, higher proportions of deaths in people younger than 65 years old were due to stroke 
in American Indians compared to Whites for both men (36% vs. 11%) and women (28% 
vs. 7%).90 
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B.5 Covert Vascular Brain Injury in American Indians 
The American Heart Association has cited research suggesting a large, mostly 
unrecognized burden of cerebrovascular disease among the US Native population.91 
Other than the recently completed SHSS for which results are not yet available, however, 
we could find no published research that has evaluated covert VBI in American Indians 
or Alaska Natives. 
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C. Manuscript 1. Comparing stroke incidence and survival in American 
Indians, Blacks, and Whites: the Strong Heart Study and Atherosclerosis Risk in 
Communities Study 
 
Clemma J. Muller, Alvaro Alonso, Jean Forster, David Vock, Rebecca Gottesman, 
Wayne Rosamond, W.T. Longstreth, Jr., Richard F. MacLehose 
 
C.1 Overview 
Background and Purpose. Stroke incidence and post-stroke mortality have been 
reported as being higher in American Indians than other US racial groups, but previous 
cross-study comparisons have been unable to account for risk factors or underlying 
trends. We pooled data from the Strong Heart Study, a longitudinal study of 
cardiovascular disease in American Indians, and the Atherosclerosis Risk in 
Communities Study, a longitudinal study that included both Blacks and Whites, to 
compare stroke incidence and post-stroke survival in these three groups.  
Methods. Both studies launched in the late 1980s, with similarities in study design 
that facilitated pooled analysis. We used Cox regression to compare stroke hazards in 
American Indians (n = 4111) vs. Blacks (n = 3765) and Whites (n = 10,413), with 
attained age as the time scale and stratified by birth year tertile (1914-1930, 1931-1937, 
and 1938-1947) to accommodate effect modification. Among the subset of participants 
who experienced incident stroke during follow-up, we used logistic regression to estimate 
differences in 30-day and 1-year post-stroke mortality for American Indians (n = 310) vs. 
Blacks (n = 416) and Whites (n = 613). All effect estimates are presented before and after 
adjusting for confounding by demographic and risk factor variables. 
Results. In the unadjusted analysis of stroke incidence American Indians had lower 
hazard ratios (HR) than Blacks across all birth cohorts (1914-1930: HR = 0.9 (95% CI = 
0.7, 1.1); 1931-1937: HR = 0.9 (95% CI = 0.7, 1.2); 1938-1947: HR = 0.9 (95% CI = 0.7, 
1.2)). In adjusted models, magnitude of associations increased across tertile (oldest to 
youngest cohort HR = 0.8 (95% CI = 0.6, 1.0); 0.7 (95% CI = 0.5, 1.0); and 0.6 (95% CI 
= 0.4, 0.8)). In the unadjusted analysis American Indians had higher stroke incidence than 
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Whites, with increasing magnitude across tertile (1914-1930: HR = 1.6 (95% CI = 1.3, 
2.0); 1931-1937: HR = 2.2 (95% CI = 1.7, 2.8); 1938-1947: HR = 2.7 (95% CI = 2.0, 
3.6)). Magnitude of associations greatly attenuated after confounder adjustment (oldest to 
youngest tertile HR = 1.1 (95% CI = 0.9, 1.5); 1.2 (95% CI = 0.9, 1.6); and 1.1 (95% CI 
= 0.8, 1.5)), with differences in diabetes prevalence accounting for most of the change. 
Among people who experienced stroke during follow-up, American Indians had higher 
30-day mortality than Blacks and Whites (21% vs. 9% and 12%, respectively). After 
confounder adjustment, American Indians had higher risk ratios (RR) compared to Blacks 
(RR = 2.6 (95% CI = 1.4, 3.9)) and Whites (RR = 2.0 (95% CI = 1.1, 3.0)). American 
Indians had higher 1-year mortality compared to Blacks and Whites (31% vs. 22% and 
21%, respectively), with RRs after confounder adjustment in comparison to Blacks (RR = 
1.4 (95% CI = 0.9, 1.8)) and Whites (RR = 1.4 (95% CI = 0.9, 1.9)) that were attenuated 
compared to the 30-day mortality comparisons. 
Conclusions. In this pooled analysis American Indians had lower stroke risk than 
Blacks and only slightly higher stroke risk than Whites after adjusting for confounders 
that included prevalent diabetes. Post-stroke mortality was substantially higher in 
American Indians than Blacks or Whites, especially within 30 days after the stroke event. 
American Indians are underrepresented in research on stroke incidence and post-stroke 
survival; the latter may be a particularly important focus for future studies to address 
stroke disparities in this population. 
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C.2 Introduction 
Approximately 800,000 strokes occur annually in the US.92,93 Compared to other 
racial groups, American Indians and Alaska Natives have among the highest burdens of 
many stroke risk factors, including hypertension, diabetes, obesity, and smoking.42,85,94 
Data collected in 2013 by the Behavioral Risk Factor Surveillance System showed higher 
self-reported prevalent stroke for American Indians and Alaska Natives ≥ 18 years old 
(4.6%) than for all other racial groups, including Blacks (4.0%) and Whites (2.5%).7 
Stroke mortality for American Indians is generally reported as lower than for other racial 
groups and Hispanics,95,96 but racial misclassification often leads to underestimating 
disease-specific mortality rates in American Indians and Alaska Natives.88,89,97,98 
Although American Indians and Alaska Natives are conventionally treated as a single 
group when reporting national health statistics, heterogeneity in stroke morbidity and 
mortality is evident within the US Native population.83 In spite of these statistics, 
American Indians are underrepresented in public health research on stroke incidence and 
mortality.52,99,100  
Information on stroke incidence in American Indians derives mainly from the 
Strong Heart Study (SHS), a population-based cohort study of cardiovascular disease in 
4549 American Indians from three geographic regions. Data from the SHS suggested that 
American Indians have higher stroke incidence than Whites and Blacks in other 
prospective studies,2 but no longitudinal cohorts exist that allow direct comparison to 
other racial groups. Population-based estimates of stroke disparities in American Indians 
have therefore been restricted to external comparisons between the SHS and other 
studies. Comparison of stroke incidence in this context is difficult, however, due to 
different durations of follow-up and different distributions of other risk factors across 
cohorts. 
The Atherosclerosis Risk in Communities Study (ARIC) is a large, population-
based prospective cohort study that recruited participants from four sites across the US.3 
ARIC enrolled both Blacks and Whites to allow direct comparison of stroke outcomes in 
these two groups.4,101-103 The SHS and ARIC share many similarities in study design and 
  13 
timelines: baseline exams began in 1988 for SHS participants who were then 45-74 years 
old, and in 1987 for ARIC participants who were then 45-64 years old. In this analysis we 
pooled SHS and ARIC data to compare stroke morbidity and mortality in American 
Indians vs. Blacks and Whites. Our aims were to estimate racial differences in stroke 
incidence among people who were free of stroke at baseline, and in post-stroke survival 
among people who experienced stroke during follow-up. Our a priori hypotheses were 
that American Indians in the SHS would have higher stroke incidence and poorer survival 
than their Black and White counterparts in ARIC, even after accounting for age, sex, and 
other influential stroke risk factors. 
C.3 Methods 
Human Subjects Protections 
The Institutional Review Board at the University of Minnesota and publications 
committees for the SHS and ARIC approved these analyses. We obtained all necessary 
tribal approvals prior to submission of the manuscript for publication. 
Study Populations 
The SHS was launched in 1988, funded by the National Heart, Lung, and Blood 
Institute to study longitudinal risk factors for cardiovascular disease in American 
Indians.1 The SHS comprised 13 tribes in three regions: Southwest, Southern Plains, and 
the Northern Plains. All tribal members aged 45-74 years were invited to participate, with 
a total baseline enrollment of 4549 people. Data collection included detailed personal 
history and lifestyle questionnaires, a clinical exam, and laboratory measurements with 
blood samples. The SHS conducted follow-up and community surveillance to adjudicate 
cardiovascular disease events and mortality, most recently through December 31, 2008. 
The ARIC Study was funded by National Heart, Lung, and Blood Institute to 
investigate patterns and causes of atherosclerosis and cardiovascular disease in a cohort 
comprising Black and White adults who were 45-64 years old at the baseline exam 
(1987-1989).3 ARIC included four field sites (Washington County, MD; Forsyth County, 
NC; Jackson, MS; Minneapolis suburbs, MN). Each site used tailored probability-
sampling methods to recruit a population-representative cohort. The final cohort (n = 
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15,792) was 55% female and 27% Black.104 Semi-annual telephone interviews were 
conducted to assess hospitalizations, self-reported events, and overall health status. 
Adjudicated events and mortality are available for ARIC participants through December 
31, 2011.   
Stroke Ascertainment 
The SHS established a rigorous surveillance and adjudication process for stroke, 
with diagnostic criteria based on international standards.1,105 Mortality surveillance was 
conducted by examination of State Health Department death certificate data; Indian 
Health Service, autopsy, or coroner’s report records; and key informant interviews with 
physicians or family members. Morbidity surveillance was based on hospital chart 
abstraction and personal interview of participants. A nosologist reviewed putative events 
for ICD-9 criteria (codes 431-437). Two independent physicians reviewed potential fatal 
and nonfatal strokes, and adjudication by the full SHS Mortality Committee resolved 
disagreements. Two neurologists further reviewed stroke-related events for a final 
diagnosis (not a stroke; possible stroke; definite stroke) and confirmation of ICD-9 
classification. This surveillance protocol may have failed to capture some strokes, 
especially nonfatal events that occurred in cohort members who migrated out of the 
participating SHS communities. Nevertheless, the well-enumerated and relatively closed 
tribal populations in the SHS led to mortality and morbidity follow-up rates generally 
exceeding 99%.2,106,107  
The ARIC protocol for stroke adjudication was conducted in two phases.4 First, 
putative stroke-related hospitalizations or deaths were identified in annual telephone 
contacts with participants or next of kin, or by review of local hospital discharge records 
and death certificates. Hospitalizations were flagged for abstraction if records contained 
ICD-9 codes (430-438) or keywords relevant to cerebrovascular disease. Putative events 
were also identified based on reference to diagnostic magnetic resonance imaging, other 
cerebral imaging, or time spent in a neurovascular intensive care unit. Second, formal 
adjudication began with standardized abstraction of death and hospital records by a single 
trained nurse. Abstracted information was then classified by computer algorithm as 
ischemic stroke (thrombotic or lacunar infarcts, cardioembolic), hemorrhagic stroke 
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(subarachnoid or intracerebral hemorrhage), possible cryptogenic stroke, out-of-hospital 
fatal stroke, or non-stroke using National Stroke Survey criteria.108 Information was 
independently reviewed and classified by an ARIC neurologist or study physician, with 
final event status determined by computer-physician agreement. Disagreement was 
resolved by a second independent physician reviewer.  
Measures 
Cohort and Demographics  
Race (American Indian; Black; White) and cohort (SHS; ARIC) were each defined 
using categorical variables. Other demographic variables included baseline age, sex, and 
years of education.  
Stroke Incidence and Survival  
We classified each person according to his or her first incident stroke (none, any) 
and calculated a variable reflecting age at stroke, death, loss to follow-up, or 
administrative censoring. For each person who experienced incident stroke, we calculated 
binary indicators of 30-day and 1-year post-stroke survival.  
Covariates 
Covariates for the pooled analysis reflect stroke risk factors measured at the 
baseline exams that were assessed similarly enough or could be standardized post hoc to 
minimize study-specific differences across cohorts. Current alcohol consumption in the 
SHS was identified by positive endorsement of drinking at least 12 alcoholic beverages in 
one’s life, drinking alcohol in the past month, and usually drinking ≥ 1 beverage per 
week;109 current alcohol consumption in ARIC was identified by positive endorsement of 
presently drinking alcoholic beverages and of usually drinking ≥ 1 alcoholic beverage 
(wine, beer, or hard liquor) per week.110 Current smoking in the SHS was identified by 
positive endorsement of smoking at least 100 cigarettes in one’s life and smoking 
cigarettes at the time of the exam;109 current smoking in ARIC was identified by positive 
endorsement of smoking at least 400 cigarettes in one’s life and smoking cigarettes at the 
time of the exam.111 Body mass index (kg/m2) was measured during the clinical exams 
for both cohorts. We included blood lipids in the analysis (LDL, HDL) even though they 
have been inconsistently associated with incident stroke in the two cohorts.2,102,112-114 
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Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood 
pressure ≥ 90 mmHg, or use of antihypertensive medication. Borderline hypertension was 
defined as systolic or diastolic blood pressure = 120-139 or 80-89 mmHg, respectively, 
without prevalent hypertension. We calculated a variable indicating good blood pressure 
control (≤ 140/90 mmHg) measured at the baseline exam. The SHS defined prevalent 
diabetes as fasting glucose ≥ 126 mg/dL, 2-hour glucose tolerance test blood glucose ≥ 
200 mg/dL, previous physician diagnosis of diabetes, or use of insulin or hypoglycemic 
oral medication. Diabetes was defined similarly in ARIC except that the 2-hour glucose 
tolerance tests were not performed, therefore we standardized prevalent diabetes by 
removing cases in the SHS that were indicated only by glucose tolerance test results. 
Impaired glucose metabolism was defined as fasting glucose = 110-125 mg/dL without 
prevalent diabetes,2 and for all participants we created a variable indicating fasting 
glucose ≤ 125 mg/dL at the baseline exam. Both cohorts assessed prevalent coronary 
heart disease and myocardial infarction, and congestive heart failure at the baseline exam.  
Analysis  
Stroke Incidence 
To create the pooled data set we excluded ARIC participants with race other than 
Black or White (n = 48), participants with prevalent stroke in SHS (n = 36) or ARIC (n = 
286), and ARIC participants with unknown baseline stroke status (n = 362). We then 
excluded participants with missing data for any variable used in the analysis (402 
American Indians, 399 Blacks, 519 Whites). We estimated race- and sex-specific stroke 
rates in two ways. First, we estimated stratified rates per 10,000 person-years, with years 
since baseline as the time scale and with baseline age standardized to the 1990 US 
Census as was done for the previous analysis in the SHS.2 Second, we estimated stratified 
rates per 10,000 person years for successive attained age thresholds (≥ 45, ≥ 55, ≥ 65, and 
≥ 75 years old). Cox regression was used to compare stroke hazards with attained age as 
the time scale, so that each participant entered the model at his or her baseline age. We 
truncated attained age at 90 years old, which was the maximum attained age in ARIC. 
Only 44 SHS participants were older than 90 as of the most recent adjudication ending 
December 31, 2008. Cox regression models were specified in three ways: 1) unadjusted, 
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2) adjusting for sex and birth year, and 3) additionally adjusting for lifestyle and health 
factors measured at baseline (education, alcohol consumption, smoking, body mass 
index, hypertension, diabetes, and cardiovascular disease). Because study site was 
colinear with race for all SHS and most ARIC locations, this variable was not included as 
a covariate in the pooled analysis. Models adjusting for health factors treated 
hypertension as a 3-category ordinal variable and included an indicator of poor blood 
pressure control. Diabetes was similarly modeled as an ordinal variable including an 
indicator of high fasting glucose. We tested for effect measure modification between race 
and sex as well as race and birth year. Analyses were stratified if effect measure 
modification was present. Results are presented as point estimates with 95% confidence 
intervals, and we tested the proportional hazards assumption for all models.  
Post-Stroke Survival 
This analysis was restricted to the subset of participants who experienced incident 
stroke during follow-up. We used logistic regression to estimate racial differences in 30-
day and 1-year post-stroke mortality. Similar to the analysis of incident stroke, we 
estimated three specifications: 1) unadjusted; 2) adjusted for sex, birth year, and age at 
stroke event; and 3) additionally adjusted for lifestyle factors and prevalent disease. We 
tested for effect measure modification between race and sex, and between race and birth 
year. We used marginal standardization to report risk differences (RD) and risk ratios 
(RR) for American Indians compared to Blacks and Whites.115 We used Stata version 
13.1 (StataCorp, College Station, TX) for all analyses. 
C.4 Results 
Table C.1 gives descriptive statistics for the 18,289 stroke-free participants of the 
SHS and ARIC who were included in the analysis. American Indians in the SHS had far 
lower percentages of people with post-secondary education than Blacks and Whites in 
ARIC, and higher percentages with self-reported current smoking. American Indians and 
Whites had lower prevalence of hypertension than Blacks, but American Indians had the 
highest prevalence of borderline hypertension. American Indians also had much higher 
percentage of people with prevalent diabetes.  
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Although American Indians in the SHS had lower prevalence of hypertension than 
Blacks in ARIC, among people with hypertension American Indians had higher mean 
systolic blood pressure than both Blacks and Whites (Table C.2, top). Hypertensive 
American Indians were also less likely than their Black and White counterparts to be 
medicated and in good control at the baseline study exam. Among participants with 
diabetes, American Indians had higher mean fasting glucose and lower percentages of 
people with fasting glucose ≤ 126 mg/dL than their Black and White counterparts in 
ARIC  (Table C.2, bottom).  
American Indians had fewer mean years elapsed between the baseline exam and 
stroke onset than Blacks and Whites (Table C.3). American Indians and Blacks had 
similar mean age at stroke onset and both had younger mean age than Whites; however, 
American Indians had younger mean age than Blacks when SHS data were restricted to 
the baseline ages represented in ARIC. When baseline age data were standardized to the 
1990 US Census and with years since baseline exam as the time scale, American Indians 
had lower stroke rates than Blacks and higher rates than Whites for both women and men. 
Using attained age as the time scale, stroke rates were generally lower for American 
Indian women and men compared to Blacks, though differences were smaller among 
people with older attained age. Rates for both American Indians and Blacks were 
consistently higher than for Whites regardless of attained age.  
In the Cox regression analysis for the total sample (Table C.4), American Indians 
had similar stroke risk compared to Blacks (unadjusted HR = 0.9 (95% CI = 0.8, 1.1)) 
and higher stroke risk than Whites (unadjusted HR = 2.0 (95% CI = 1.8, 2.3)). Covariate 
adjustment resulted in larger magnitude of effect estimates for the former comparison and 
smaller magnitude for the latter. Models that were unadjusted or adjusted only for sex 
and birth year showed violation of proportional hazards between American Indians and 
Whites, and both covariate-adjusted models indicated significant interaction between race 
and birth year (p < 0.001). We estimated all subsequent stroke incidence models 
separately by birth year tertile (1914-1930; 1931-1937; and 1938-1947) and verified no 
residual interactions or violations of the proportional hazards assumption. In the stratified 
models American Indians had lower stroke risk than Blacks before and after covariate 
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adjustment in all three birth cohorts, with highest magnitude of difference in the youngest 
birth cohort after accounting for prevalent hypertension and diabetes. American Indians 
had higher stroke risk compared to Whites in all unadjusted models, with differences of 
larger magnitudes in younger birth cohorts. HRs attenuated dramatically after full 
covariate adjustment, however, with nearly equal incidence when accounting for 
prevalent hypertension and diabetes regardless of birth year. HRs for covariates are 
shown in the Appendix. 
Univariate confounder adjustment (results not shown) revealed that the change in 
HRs after adjusting for confounding by lifestyle and health factors was almost entirely 
driven by the higher prevalence of diabetes in American Indians than in Blacks and 
Whites, though the impact for comparisons to Blacks was slightly offset by the higher 
prevalence of hypertension in the latter. Diabetes prevalence declined from oldest to 
youngest birth cohorts for all three racial groups (data not shown), but the relative 
prevalence increased across tertiles for American Indians vs. both Blacks (prevalence 
ratios = 2.0, 2.4, and 2.9 from oldest to youngest tertile) and Whites (prevalence ratios = 
4.1, 6.3, and 7.4 from oldest to youngest tertile).  
Among the 1339 people who experienced incident stroke during follow-up, 
cumulative mortality and mean age at death in American Indians were similar to Blacks 
and higher than Whites (Table C.5). Compared to both Blacks and Whites, however, 
American Indians had fewer mean years from stroke to death as well as higher 30-day 
and 1-year mortality. In fact, 30-day mortality in American Indians was strikingly similar 
to 1-year mortality estimates in Blacks and Whites. Mortality RDs persisted after 
covariate adjustment (Table C.6). Differences attenuated for 1-year mortality 
comparisons, although American Indians continued to show higher risk on the absolute 
and multiplicative scales. Covariate adjustment had little impact on comparisons for 1-
year mortality. 
C.5 Discussion 
We found that American Indians in the SHS had slightly lower stroke risk than 
Blacks, and higher risk than Whites in ARIC before adjusting for lifestyle and health 
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covariates. When stratified by birth year tertile, HRs for American Indians vs. Whites 
increased substantially from the oldest to youngest birth year tertiles. This finding is 
congruent with research showing that Whites benefitted more than other racial groups 
from recent declines in stroke morbidity and mortality.95 Among people who experienced 
incident stroke, American Indians in the SHS had higher 30-day mortality than Blacks or 
Whites in ARIC. Differences were less striking for 1-year mortality, although American 
Indians still showed higher risk than Blacks or Whites.  
In the only previous publication on incident stroke in American Indians using SHS 
data through 2004, the authors reported rates for women (653 per 100,000 person years) 
and men (707 per 100,000 person years) that were higher than rates for Blacks and 
Whites in other studies.2 In our analysis, age-standardized rates for American Indian men 
and women using stroke events through 2008 were lower than in the previous 
publication, but were still higher than rates for Blacks and Whites (288 and 179 per 
100,000 person-years, respectively) used for external comparisons by the previous 
study’s authors.87 Rates from both analyses of SHS data were also higher than previously 
reported for Blacks and Whites in ARIC,4 but the latter were not age-standardized and 
external comparisons are problematic given the differences in baseline ages between the 
two cohorts. By specifying attained age as the time scale for the Cox regression analysis 
of incident stroke, we attempted to minimize concerns of bias from the older baseline age 
range for American Indians in the SHS. Our analysis also expanded previous 
comparisons to include direct estimation of HRs and standardization of definitions for 
key risk factors such as diabetes and hypertension.  
Not surprisingly, research suggests that racial disparities in stroke incidence are 
linked to disproportionate burdens of stroke risk factors, though most studies have 
focused exclusively on Blacks and very few publications include American Indians or 
Alaska Natives.59,61,62,116,117 After adjusting for covariates including diabetes and 
hypertension, HRs were greatly attenuated for comparisons between American Indians 
and Whites but were magnified for comparisons between American Indians and Blacks. 
Also notable was the larger impact of covariate adjustment in younger birth cohorts for 
comparisons to both Blacks and Whites, patterns which mirrored the steep increase in 
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diabetes prevalence ratios across birth year tertiles—especially for comparisons between 
American Indians and Whites. To some extent, then, trends we observed across birth 
cohorts may reflect the emerging diabetes epidemic among American Indians during the 
20th Century.   
Declining stroke incidence since the 1960s also coincided with declining mortality, 
leading to stroke being downgraded from 3rd to 4th most common cause of death in the 
US.47 In recent years the decline in stroke mortality has plateaued,47,48 and as with stroke 
incidence racial and ethnic minorities may have not experienced the same improvements 
as Whites. In our analysis 30-day mortality in American Indians resembled 1-year 
estimates in Blacks and Whites, clearly showing that American Indians in the SHS who 
experienced stroke tended to die much sooner than their Black and White counterparts in 
ARIC. This striking disparity could reflect barriers to timely access of acute healthcare 
services in the primarily rural, reservation communities of the SHS; greater stroke 
severity or poorer underlying health status in American Indian stroke patients; disparities 
in healthcare quality or rehabilitation services; or some combination of these and other 
explanations. Among people who survived at least 30 days, however, the difference in 
death rates was markedly lower as shown by the smaller racial differences in 1-year 
mortality.  
The inferential implications of adjusting for risk factors depend on one’s view of 
race as an exposure for disease.118 Two opposing perspectives have historically been 
pitted against each other with strong proponents and detractors on both sides.119 In one, 
race is an innate biological construct that directly acts to cause disease, such as genetic 
differences in response to certain medications. In the other, race is an externally imposed 
label that affects other people’s decisions or actions, such as physicians providing 
differential treatment to patients based on race. Although some debate persists,120-125 race 
as a biological construct has been debunked in the genetic, clinical, and epidemiologic 
literature.126-131 If race is viewed as an innate cause of stroke, adjusting for other health 
conditions can be viewed as conditioning on intermediate factors.132 If race is viewed as a 
socially invented caste system, then adjusting for other health conditions can be viewed 
as appropriately controlling for confounding due to discrimination directed at certain 
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racial groups that in itself causes higher burdens of stroke risk factors.133 In either 
scenario, adjusting for mediating factors requires assumptions of no uncontrolled 
confounding between the mediators and the outcome. Some epidemiologists have 
recently proposed a causal model within which racial “effects” can be identified by 
articulating interventions on factors such as socioeconomic status that overlap with 
race,134 or an etiologic model in which a temporal cascade of causes and effects could 
bring about associations between two factors (race and stroke) that may not by 
themselves satisfy conventional criteria for causal inference.135 The latter especially 
facilitates placing epidemiologic study of racial disparities in a social justice context.136 
In this analysis, we opted to present results both with and without covariate adjustment. 
The raw data are useful for demonstrating disparities in the lived experience of American 
Indians, while covariate adjustment may help elucidate targets for intervention to reduce 
disproportionate burdens of stroke morbidity and mortality, such as diabetes prevention 
or improved access to emergency healthcare, even while acknowledging unresolved 
questions about exact causal relationships. 
C.6 Limitations 
This analysis has several limitations. First, because American Indian race is colinear 
with the SHS we cannot know with certainty the extent to which comparisons to Blacks 
and Whites in ARIC are influenced by differences in study design. By restricting the 
pooled analysis to the SHS and ARIC cohorts, however, we attempted to mitigate this 
limitation by combining data sets with similar designs, timelines, and ages of 
participants. Although the SHS enrolled older participants (45-74 years old at baseline) 
than ARIC (45-64 years old at baseline), setting attained age as the time scale allowed 
comparisons between all participants who reached any given age during follow-up. 
Nevertheless, differences in stroke ascertainment cannot be ruled out as a partial 
explanation for differences in stroke outcomes between SHS and ARIC participants, 
especially since ARIC adjudication did not include out-of-hospital fatal strokes. Second, 
it is unclear to what extent our results can generalize to broader statements about stroke 
incidence or post-stroke mortality in the larger populations of American Indians, Blacks, 
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and Whites across the US. Nearly all of the Black participants in ARIC were enrolled at 
the Mississipi (89%) or North Carolina (10%) field sites; both states are located in the so-
called “stroke belt” of the US,21 and we cannot evaluate stroke incidence in Blacks from 
outside this region. Similarly, our study should not be interpreted as reflecting stroke 
disparities in Alaska Natives, although American Indians and Alaska Natives are 
frequently grouped together in public health research. Third, as described in the previous 
section the covariate-adjusted analysis must be interpreted as potentially adjusting for 
intermediates between race and stroke incidence or post-stroke mortality. Fourth and 
relatedly, the inferential analysis relies on untestable assumptions of no uncontrolled 
confounding; no bias from sparse data in some combinations of covariates; correct 
specification of the Cox and logistic regression models; and consistency of exposure, 
meaning that any given race label confers the same health effects on everyone to whom it 
is applied. Under the sociocultural cause model of racial disparities this assumption is 
unlikely to be met. Instead, the meaning of race and its impact on health likely varies 
across culture, geography, and time. In this paper, racial disparities must be interpreted as 
reflecting overall associations while acknowledging the likelihood that the population-
level differences may not apply equally to all individuals.  
C.7 Summary and Conclusion 
American Indians in the SHS had lower stroke risk than Blacks and higher risk than 
Whites in ARIC. After adjusting for confounders including hypertension and diabetes, 
differences were strengthened for comparisons to Blacks and attenuated for comparisons 
to Whites. The strongest impact of covariate adjustment was observed in the youngest 
birth years tertile. American Indians who experienced stroke had at least 2-fold higher 
risk of 30-day post-stroke morality than both Blacks and Whites, with elevated risks of 
smaller magnitude for 1-year post-stroke mortality.  
 American Indians and Alaska Natives comprise 1.7% of the US population, or 5.2 
million people.137 American Indians have higher stroke prevalence than any other racial 
or ethnic group;51 die from stroke at younger ages than Whites;90 and have among the 
highest burdens of stroke risk factors.42,83 Nevertheless, multiple reports have concluded 
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that Native people are underrepresented in stroke research.52,99,100,138 Our analysis 
suggests that the diabetes epidemic in American Indians may be a strong factor in the 
high stroke rates among SHS participants, and that targeting diabetes prevention and 
treatment is critical to reducing stroke disparities in this population. Our analysis also 
highlights profound disparities in post-stroke survival, especially in the month 
immediately following the event. Further epidemiologic and experimental studies are 
needed to understand and intervene on the causes for earlier post-stroke death risk in 
American Indians. 
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Table C.1. Baseline characteristics by age, study, and race among cohort participants who were 






 (n = 4111) (n = 3765) (n = 10,413) 
Age:    
45-54 50% 58% 51% 
55-64 33% 41% 48% 
65-74 18% 1%* 1%* 
Female 60% 61% 53% 
Education:    
0-11 47% 41% 17% 
12-16 50% 28% 46% 
17+ 3% 31% 38% 
Current alcohol consumption 42% 32% 65% 
Current smoking 34% 30% 25% 
Body mass index, kg/m2 31 (6) 30 (6) 27 (5) 
Waist:Hip ratio 0.95 (0.07) 0.92 (0.08) 0.93 (0.08) 
Blood lipids:    
LDL, mg/dL 117 (34) 137 (43) 137 (38) 
HDL, mg/dL 46 (13) 55 (18) 51 (17) 
Congestive heart failure 3% 7% 4% 
Coronary heart disease (includes myocardial 
infarction) 
3% 4% 5% 
Systolic blood pressure, mmHg 127 (19) 129 (21) 118 (17) 
Diastolic blood pressure, mmHg 77 (10) 80 (12) 72 (10) 
Hypertension:    
None 29% 21% 45% 
Borderline 32% 22% 23% 
Hypertensive 39% 57% 32% 
Fasting glucose, mg/dL 148 (73) 117 (55) 104 (28) 
Diabetes:    
None 43% 69% 81% 
Impaired fasting glucose 16% 13% 11% 
Diabetic 41% 18% 8% 
SHS = Strong Heart Study; ARIC = Atherosclerosis Risk in Communities Study 
* 97 ARIC participants were 65-66 years old at baseline 
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Table C.2. Blood pressure measured at the baseline exam and antihypertensive medication 
among hypertensive cohort members (top), and fasting glucose among diabetic cohort members 
(bottom). 
 American Indian Black White 
People with hypertension (n = 1583) (n = 2155) (n = 3298) 
Blood pressure at exam:    
Systolic, mean mmHg (SD) 142 (20) 137 (23) 130 (20) 
Diastolic, mean mmHg (SD) 82 (11) 84 (13) 76 (11) 
Medication and control:**    
No medication 40% 25% 22% 
Medicated, poor control 27% 28% 17% 
Medicated, good control 33% 47% 61% 
People with diabetes (n = 1703) (n = 680) (n = 811) 
Fasting glucose at exam, mean mg/dL (SD) 211 (76) 200 (87) 172 (66) 
Fasting glucose ≤ 125 mg/dL 3% 10% 11% 
** Medication = antihypertensive drugs; good control = blood pressure < 140/90 mmHg at 
baseline exam; poor control = blood pressure ≥ 140/90 at baseline exam 
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Table C.3. Descriptive statistics for incident stroke by race for American Indians in the Strong 
Heart Study and Blacks and Whites in the Atherosclerosis Risk in Communities Study 
 American Indians Blacks Whites 
 Women Men Women Men Women Men 
 (n = 2447) (n = 1664) (n = 2309) (n = 1456) (n = 5532) (n = 4881) 
Number of strokes 189 121 243 173 280 333 
Age at stroke*, mean 
(SD) 
69 (9) 67 (9) 68 (8) 66 (8) 71 (8) 70 (7) 
Years from baseline to 
stroke, mean (SD) 
10 (5) 8 (5) 12 (6) 11 (6) 14 (7) 13 (6) 
Stroke incidence** (95% CI)  
Age-standardized† 











Attained age‡       
≥ 45 years old 







10 (7, 14) 
16 (12, 
22) 
≥ 55 years old 











≥ 65 years old 























* Mean age for American Indians with same baseline ages (45-64 years old) as Blacks and 
Whites = 65 (7) for both women and men 
** Per 10,000 person-years 
† Using 1990 US Census; time scale = years elapsed since baseline exam 
‡ Time scale = attained age up to 90 years old 
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Table C.4. Hazard ratios from Cox regression of incident stroke by race and birth cohort 
tertile. 
 American Indians vs. 
Blacks 
 American Indians vs. 
Whites 
 Hazard Ratio (95% CI)  Hazard Ratio (95% CI) 
Total Sample    
Unadjusted 0.92 (0.78, 1.06)  2.01 (1.76, 2.31) 
Adjusted for sex and birth year 0.88 (0.76, 1.02)  2.01 (1.75, 2.31) 
All covariates* 0.75 (0.64, 0.88)  1.15 (0.98, 1.35) 
Stratified by Birth Cohort Tertile    
Birth years 1914-1930    
Unadjusted 0.86 (0.69, 1.08)  1.60 (1.32, 1.95) 
Adjusted for sex and birth year 0.84 (0.66, 1.07)  1.60 (1.30, 1.98) 
All covariates* 0.79 (0.61, 1.01)  1.14 (0.90, 1.45) 
Birth years 1931-1937    
Unadjusted 0.89 (0.68, 1.18)  2.15 (1.65, 2.80) 
Adjusted for sex and birth year 0.89 (0.67, 1.17)  2.22 (1.70, 2.90) 
All covariates* 0.73 (0.54, 0.98)  1.15 (0.85, 1.55) 
Birth years 1938-1947    
Unadjusted 0.90 (0.68, 1.20)  2.66 (1.97, 3.60) 
Adjusted for sex and birth year  0.94 (0.70, 1.26)  2.83 (2.08, 3.86) 
All covariates* 0.60 (0.44, 0.84)  1.08 (0.76, 1.53) 
* Adjusted for sex, birth year, education, alcohol consumption, current smoking, body mass 
index, and prevalent cardiovascular disease, hypertension, diabetes. 
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Table C.5. Post-stroke mortality by race. 
 American 
Indian 
 Black  White 
 (n = 310)  (n = 416)  (n = 613) 
Cumulative mortality 63%  62%  54% 
Age at death, mean (SD) 70 (9)  71 (8)  75 (7) 
Years to death, mean (SD) 2.9 (4)  3.8 (4)  4.1 (5) 
30-day mortality 21%  9%  12% 




Table C.6. Racial differences in 30-day and 1-year mortality after primary stroke. 
 Unadjusted  Fully adjusted* 









30-day mortality      
American Indians vs. 
Blacks 
11 (6, 17) 2.2 (1.4, 3.0)  14 (6, 23) 2.6 (1.4, 3.9) 
American Indians vs. 
Whites 
9 (4, 14) 1.8  (1.2, 2.3)  12 (3, 21) 2.0 (1.1, 3.0) 
1-year mortality       
American Indians vs. 
Blacks 
9 (3, 16) 1.4 (1.1, 1.8)  8 (-1, 17) 1.4 (0.9, 1.8) 
American Indians vs. 
Whites 
10 (4, 16) 1.5 (1.1, 1.8)  8 (-1, 17) 1.4 (0.9, 1.9)  
RD = Risk difference; RR = Risk ratio; CI = confidence interval 
* Adjusted for sex, age at stroke event, birth year, education, alcohol consumption, smoking, body 
mass index, and prevalent cardiovascular disease, hypertension, and diabetes. 
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D. Manuscript 2: Inverse probability weighting for selection bias tailored to 
inclusion criteria in the target population: covert vascular brain injury among 
American Indians in the Strong Heart Stroke Study 
 
Clemma J. Muller, Alvaro Alonso, David Vock, Jean Forster, Astrid Suchy-Dicey, 
Richard F. MacLehose 
 
D.1 Overview 
Background and Purpose. Covert vascular brain injury (VBI) is a risk factor for 
stroke and cognitive dysfunction. The Strong Heart Stroke Study used structural cranial 
magnetic resonance imaging to assess VBI and its risk factors in 1033 surviving members 
of the Strong Heart Study, a longitudinal cohort study of cardiovascular disease in 
American Indians. All participants were ≥ 62 years old, and data may be affected by 
selection bias if exposures and outcomes are both correlated with differential survival 
over time. Marginal structural models with inverse probability weighting (IPW) are 
commonly used to adjust for selection bias, but may inadvertently introduce bias when 
weights are correlated with presence of inclusion criteria that require excluding a 
subgroup from the analysis. In this case, evaluating covert VBI requires excluding 
participants with clinical stroke. We describe a modification of traditional IPW methods 
that tailors weights to account for correlation with inclusion criteria, with analysis of 
hypertension and covert VBI (white matter hyperintensities grade and volume) presented 
as an example.  
Methods. We used logistic regression to estimate the association between prevalent 
hypertension and a binary indicator of VBI (white matter hyperintensity grade ≥ 3), and 
linear regression to estimate the same association for white matter hyperintensity volume 
as a proportion of total intracranial volume (ratio multiplied by 1000 to simplify 
presentation of results). Estimates reflected cross-sectional associations and longitudinal 
trends in hypertension from previous Strong Heart Study visits, with IPW to adjust for 
confounding and selection bias. Weights were stabilized to reflect the distribution of 
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prevalent hypertension in the target population. In addition, we tailored weights to 
account for each participant’s probability of meeting the stroke-free inclusion criterion.  
Results. After covariate adjustment the cross-sectional prevalence difference was 
7.9% (95% CI = -2, 17) for the unweighted analysis, and 8.9% (95% CI = 0, 18) using 
IPW for selection bias with stabilized weights and for weights tailored to probability of 
being stroke-free. Estimates for the mean difference in white matter hyperintensity 
volume were 0.8 (95% CI = -0.4, 2.0) for the unweighted analysis; 0.9 (95% CI = -0.2, 
2.1) with stabilized selection weights; and 0.9 (95% CI = -0.3, 2.1) with selection weights 
tailored to the stroke-free target population. In the analysis using longitudinal 
hypertension patterns, being hypertensive at all previous study visits was positively 
associated with covert VBI, but there was no apparent impact of using IPW to adjust for 
selection bias.  
Conclusions. Among elderly American Indians in the SHSS, hypertension was 
positively associated with covert VBI as measured by abnormal WMH grade and higher 
white matter/intracranial volume ratio. By tailoring selection weights proportional to 
stroke risk in the cohort, our point estimates relate to a target population aligned with 
SHSS inclusion criteria. 
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D.2 Introduction 
Covert vascular brain injury (VBI) is pathology in the brain characterized by white 
matter hyperintensities (WMH), asymptomatic hemorrhages or infarcts, and cerebral 
tissue atrophy in the absence of overt clinical symptoms.68 Covert VBI is typically 
diagnosed via magnetic resonance imaging, although it is increasingly recognized as 
comorbid with detectable changes in cognition, physical function, and mood.73,139-141 
Covert VBI predicts high risk of future stroke,142,143 and is understudied in most racial 
and ethnic minority groups. American Indians are particularly underrepresented in 
magnetic resonance imaging studies, despite notable disparities including higher stroke 
incidence and prevalence, younger age at onset and death from stroke, and higher 
burdens of VBI risk factors such as hypertension and diabetes compared to the general 
US population.2,51,83,94,144-148  
The Strong Heart Stroke Study (SHSS) was funded to evaluate covert VBI and its 
comorbidities in American Indians,149 with exams conducted from 2010-2013. The SHSS 
examined 1033 surviving members of the Strong Heart Study, a longitudinal population-
based cohort study of American Indians from three geographic regions who were 45-74 
years old when baseline exams were conducted in 1988-1990.1 The SHSS goals include 
identifying correlates of prevalent covert VBI using cross-sectional data collected at 
SHSS exams and longitudinal data previously collected by the Strong Heart Study. 
Because the SHSS comprises elderly long-term survivors of the original cohort who were 
healthy enough to undergo magnetic resonance imaging, study results could be affected 
by selection bias.150 Specifically, if covert VBI and a potential risk factor are each 
associated with lower probability of survival or participation in the SHSS, the observed 
point estimate could be biased towards showing a null or even a negative association 
between the two conditions.5  
Marginal structural models with inverse probability weighting (IPW) were 
originally used by epidemiologists to adjust for time-varying confounding in longitudinal 
data,151,152 but are commonly applied to adjust for selection bias.153-155 IPW functions by 
weighting observations based on the inverse of their predicted probabilities of being in 
the study to generate a data set in which there is no statistical association between 
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exposure and selection. The default target population usually reflects the covariate 
distribution in the total study population, but weights can be tailored for inference to the 
exposed, unexposed, or other specialized target populations.156 When studies involve 
inclusion criteria that may themselves correlate with prediction equations for constructing 
weights, such as SHSS analyses that require absence of prevalent clinical stroke, special 
care should be taken to ensure appropriate statistical inference. We constructed weights 
for IPW models to adjust for selection bias in the SHSS and tailored weights to a stroke-
free inclusion criterion. We demonstrate the method for evaluating the association 
between hypertension and covert VBI as manifested by WMH. Our aims were to 1) 
evaluate the cross-sectional association between hypertension and covert VBI measured 
by the SHSS, and 2) evaluate the association for longitudinal patterns of hypertension 
measured from 1988-2013 by the Strong Heart Study and the SHSS. Our second aim also 
included use of IPW to adjust for time-varying confounding between hypertension and 
other VBI risk factors.  
D.3 Methods 
Human Subjects Protections 
The Institutional Review Board at the University of Minnesota and publications 
committees for the Strong Heart Study and SHSS approved these analyses. We obtained 
all necessary tribal approvals prior to submission of the manuscript for publication. 
Study Population  
The Strong Heart Study was launched in 1988, funded by the National Heart, Lung, 
and Blood Institute to study longitudinal risk factors for cardiovascular disease in 
American Indians.1 Investigators partnered with 13 tribes in three geographic regions: 
Southwest, Southern Plains, and Northern Plains. All tribal members aged 45-74 years 
were invited to participate, and 4549 people were ultimately enrolled. The Strong Heart 
Study collected data in three phases over 12 years: 1988-1991 (baseline), 1993-1995, and 
1998-2000. Study visits included extensive clinical exams with electrocardiogram 
assessment of cardiac function, and laboratory analysis of blood and urine samples. At 
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each phase, follow-up was conducted to track cardiovascular disease events and 
mortality.  
Also funded by the National Heart, Lung, and Blood Institute, the SHSS was 
launched in 2010 to examine covert VBI and its correlates in all surviving members of 
the Strong Heart Study cohort.149 The SHSS was a cross-sectional study, although 
participants were drawn from the longitudinal cohort and previously collected data could 
be included in analyses of prevalent covert VBI at the SHSS exam. Exclusion criteria 
were prior surgery for cerebral aneurysm; implanted cardiac pacemaker, defibrillator, or 
artificial heart; contraindicating metal prostheses; internal electrical device such as 
cochlear implant; history of employment as a metal worker; weight exceeding 350 
pounds; and physical or cognitive inability to complete study procedures. Of the 1664 
Strong Heart Study members who were still alive at the start of SHSS recruitment, 201 
were ineligible, 261 died or were otherwise incapacitated before they could be recruited, 
and 169 chose not to participate. Data collection on the remaining 1033 participants was 
completed in December, 2013. SHSS clinic visits comprised an extensive physical exam 
and personal interview, fasting blood and urine collection, neurocognitive and 
neuropsychological testing, physical performance assessment, and structural cranial 
magnetic resonance imaging. Of the 1033 enrolled participants, 998 completed all 
components of the study visit. For SHSS analyses focused on covert VBI in the absence 
of clinical events, an additional inclusion criterion requires analyzing data only for the 
934 participants who did not have prevalent stroke. 
Measures  
Demographic data collected at the Strong Heart Study and SHSS exams included 
field site (Southwest, Southern Plains, Northern Plains), date of exam, age, sex, 
education, marital status, percentage of one’s life lived on a federal reservation, and self-
rated fluency in one’s Native language (fluent, speaks some but not fluent, none). 
Cigarette smoking was assessed by the following questions: “During your lifetime have 
you smoked 100 cigarettes or more total?”, “Do you smoke cigarettes now?”, and “On 
the average, how many cigarettes do/did you usually smoke per day?” Alcohol 
consumption was similarly assessed: “Have you ever consumed alcoholic beverages?”, 
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“If yes, when was your last drink?”, “How many alcoholic drinks do you have in a typical 
week?” and “How many days in a typical month do you have at least one drink?” Based 
on answers to these questions, smoking and alcohol use were classified as current, 
former, or never. Body mass index (kg/m2) was calculated based on measurements taken 
at the exam; obesity was defined as body mass index ≥ 30 kg/m2. High and low density 
lipoproteins (mg/dL) were measured after overnight fasting. Systolic and diastolic blood 
pressure (mmHg) reflected the average of the second and third measurements taken 
during the clinic exam. Urine samples were assayed to quantify the albumin-creatine ratio 
and categorized to indicate microalbuminuria (30-299 mg/g) or macroalbuminuria (≥ 300 
mg/g). Prevalent diabetes was defined as fasting plasma glucose ≥ 126 mg/dL, 2-hour 
glucose challenge plasma glucose ≥ 200 mg/dL (this criterion was not assessed by the 
SHSS), or use of insulin or hypoglycemic oral medication. Prevalent transient ischemic 
attack was assessed by self-report using a form developed by the Atherosclerosis Risk in 
Communities Study.157 Formal adjudication protocols were used to identify prevalent and 
incident stroke and cardiovascular disease (myocardial infarction, coronary heart disease, 
congestive heart failure).1,105 Prevalent atherosclerosis was assessed by carotid ultrasound 
during the Strong Heart Study phase 3 exams.158 
At each Strong Heart Study and SHSS exam, continuous blood pressure measures 
were combined with medical history information to create binary indicators of prevalent 
hypertension based on systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 
mmHg, or use of antihypertensive medication (ACE inhibitor, alpha 2 agonist, 
angiotensin II receptor agonist, beta blocker, calcium channel blocker, vasodilator, 
thiazide diuretic, or dihydropyradine). For the cross-sectional analysis, the exposure of 
interest was prevalent hypertension at the SHSS exam. For the longitudinal analysis, we 
created a multi-category variable for each combination of prevalent hypertension status 
across baseline, 10-year follow-up, and the SHSS (eight categories total). 
In the SHSS, cranial magnetic resonance imaging scans were conducted using 
General Electric 1.5T Signa scanners at the Southwest and Southern Plains sites, and a 
Siemens 1.5T Symphony scanner in the Northern Plains.149 For each participant, 
investigators obtained six series of images: a sagittal T1-weighted localizer, coregistered 
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5mm axial T1, T2, and T2* (susceptibility)-weighted images in the anterior 
commissure/posterior commissure plane, 3mm axial FLAIR images, and 1.5mm sagittal 
T1-weighted volumetric gradient echo images. Scans were read at the University of 
Washington by two trained neuroradiologists using established scoring criteria.78,159 
Volumetric measures included gray matter (total brain, intracranial, left and right 
hippocampus) and white matter as a proportion of total intracranial volume. For this 
analysis we multiplied the white matter volume/intracranial volume ratio by 1000 to 
simplify presentation of results. For WMH, grade was quantified on a 10-point scale by 
SHSS neuroradiologists, with covert VBI defined as abnormal WMH grade ≥ 3. 
Missing Data 
Even small amounts of missing data in variables used to estimate inverse 
probability weights can lead to large numbers of observations dropped from a complete-
case analysis, especially when predicted probabilities are measured for two selection 
mechanisms (death and non-participation) over multiple phases of data collection. To 
preserve sample size, we used multiple imputation by chained equations with 100 
repetitions to impute missing values for all variables used in the IPW analysis.160 Missing 
values for variables from the 10-year follow-up exam were only imputed for people who 
participated in the 10-year follow-up, and missing values for the SHSS exam were only 
imputed for SHSS participants. We used all 100 imputed data sets to estimate predicted 
probabilities for the IPW analysis, with each person’s average value retained to calculate 
weights in the final data set. For descriptive statistics of individual variables in the SHSS 
we used the mean values of each variable across all 100 imputed data sets, rounded to the 
nearest integer for ordered categorical factors (education and albuminuria).  
Inverse Probability Weighting for Confounding 
As outlined in a recent overview,161 IPW for control of time-varying confounders is 
accomplished in four steps: 1) for each time point at which data were collected, fit a 
model to predict exposure given current and past covariates; 2) for each time point, use 
the model to estimate each individual’s predicted probability of experiencing his or her 
observed exposure status; 3) for each individual, create a weight that is proportional to 
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the inverse of the product of his or her predicted probabilities from step 2; and 4) use the 
product of estimates from step 3 as probability weights in the inferential analysis. Step 4 
creates a pseudopopulation in which there is no association between confounders and 
exposure. IPW models can become unstable when very large weights arise from very low 
predicted probabilities, so weights are typically stabilized by replacing the numerator 
with the predicted probability of each individual having their observed exposure status 
conditioned on previous exposure. Final effect measures estimate the overall difference in 
the outcome that would be observed if the entire target population were exposed 
compared to if the entire target population were unexposed. In its simplest application, 
IPW can be used to control for confounding at a single time point using cross-sectional 
data.162 
We used IPW to adjust for confounding in the analysis of hypertension and covert 
VBI in the SHSS. For the cross-sectional analysis we estimated unstabilized weights as 
the inverse of the predicted probability of each SHSS participant’s observed hypertension 
status, conditioned on potential confounders (study site, age, sex, baseline education, 
marital status, body mass index, smoking status, high- and low-density lipoproteins, 
prevalent diabetes, and prevalent cardiovascular disease) measured during the SHSS 
exam. These weights were stabilized by replacing the numerators with the overall 
prevalence of each person’s observed hypertension status:  
 
[1] 
Where Pr(HSHSS = hSHSS) is the mean predicted probability of observed hypertension 
status using imputed data for the SHSS. Because we restricted the cross-sectional 
analysis to data collected during the SHSS exams, stabilized numerators did not condition 
on previous hypertension status. 
We estimated weights for the longitudinal analysis using the same variables in a 
similar manner as described for the cross-sectional analysis, except that weights were 
estimated separately for baseline, 10-year follow-up, and the SHSS. We calculated the 
predicted probability of each person’s observed hypertension status at phase i conditioned 
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on selection into phase i, time-varying covariates at phase i, hypertension and time-
varying covariates at the previous phase (phase i – 1) for 10-year follow-up and the SHSS 
only, and time-invariant covariates (field site, sex, baseline education) measured at 
baseline. The inverse of these predicted probabilities generated unstabilized confounding 
weights for that phase. We stabilized the confounding weights by replacing the numerator 
with the overall probability of observed hypertension status (for baseline) or the predicted 
probability of observed hypertension status at phase i conditioned on hypertension at 
phase i – 1 (for 10-year follow-up and the SHSS): 
 
[2] 
where Pr(Hi = hi|Sel = 1, Hi-1) is the probability of observed hypertension status at phase i 
conditioned on participation in phase i and hypertension at phase i – 1, if applicable. In 
the denominator of equation 2 Ci, Ci-1 and CB are confounders measured at phase i, phase 
i – 1 if applicable, and at baseline, respectively. The product of phase-specific 
confounding weights comprised the final time-varying confounding weight for 
longitudinal analysis: 
 [3] 
Inverse Probability Weighting for Selection Bias 
IPW can be used to adjust for selection bias when sufficient data are available to 
estimate predicted probabilities of attrition over time.155 Statistical models are weighted 
so individuals contribute information proportional to their predicted probability of being 
in the study, creating a pseudopopulation in which there is no association between 
exposure and selection. Predicted probabilities for IPW can be structured to separately 
account for attrition by death and non-participation of survivors; these estimates are then 
inverted and multiplied to generate weights in which final selection probabilities are 
balanced within each covariate stratum. As with IPW for confounding, selection weights 
are typically stabilized by setting the numerator equal to the predicted probability of 
selection conditioned only on exposure status.  
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We used data from the baseline and 10-year follow-up exams to predict survival 
and participation of survivors in the SHSS. The 10-year follow-up was approximately 
midway between baseline and the SHSS, and we chose this approach as a compromise 
between only using baseline data to estimate selection weights (simpler, but more prone 
to bias from time-varying confounding) and using all available Strong Heart Study data 
including the 5-year follow-up exams (less risk of bias from time-varying confounding, 
but more risk of bias from model misspecification and heavier reliance on imputation). 
With the exception of magnetic resonance imaging outcomes collected at the SHSS 
exam, all variables listed in Measures were considered for models predicting survival and 
participation of survivors.  
For the 10-year follow-up and the SHSS visits we first used imputed data to 
estimate the mean predicted probability of survival to that phase, conditioned on 
observed hypertension status, time-varying predictors at the previous phase (Ci-1), and 
fixed predictors measured at baseline (CB): Pr(Survi = 1|Hi-1, Ci-1, CB). Note that CB was 
only included as a vector separate from Ci-1 for the SHSS visit. Next we restricted the 
data to survivors at phase i and used imputed data to estimate the mean predicted 
probability of participation in phase i, conditioned the same factors as for survival 
probabilities: Pr(Parti = 1| Survi = 1, Hi-1, Ci-1, CB). Each person’s unstabilized weight for 
selection at phase i was calculated as the product of the inverse of predicted probabilities 
for survival and participation, stabilized by replacing numerators with the predicted 
probabilities of selection conditioned on previous exposure and a subset of baseline 
predictors (field site, sex, age, prevalent diabetes, and prevalent cardiovascular disease):  
 
[4] 
The product of these interval-specific weights (baseline to phase 3, phase 3 to the SHSS) 
constituted the final stabilized selection weights from baseline through the SHSS: 
 [5] 
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Tailoring weights for inclusion criteria 
The population of interest for studies of covert VBI is often limited to people who 
have not experienced overt clinical events, namely strokes, but who may have 
asymptomatic pathology that could benefit from medical intervention. Therefore, 
although all living Strong Heart Study cohort members were invited to participate, 
analysis of covert VBI in the SHSS will often require excluding observations with 
prevalent stroke. We were concerned about the potential for correlation between 
predicted probability of attrition and risk of experiencing stroke prior to the SHSS. If 
covariate profiles associated with low probability of selection into the SHSS were also 
associated with high risk of stroke, then the resulting large selection weights could over-
correct for the missing observations people with these combinations of risk factors are 
assumed to represent. Conceptually, in this scenario the pseudopopulation generated by 
IPW would not reflect the desired stroke-free target population. We therefore tailored the 
numerators of selection weights from equation 5 to jointly account for each person’s 
predicted probability of selection and of being stroke-free at their SHSS exam.156  
If selection probability and stroke risk were independent of each other, then their 
joint probability in the numerator of stabilized weights could be easily estimated as the 
product of the individual probabilities: Pr(Sel = 1, Stk = 0) = Pr(Sel = 1) × Pr(Stk = 0). 
Because people with higher stroke risk are likely to have low probability of survival, 
however, the probabilities are not independent and so instead we modeled their joint 
association. For all 1031 SHSS participants who were stroke-free at baseline, we used 
imputed baseline data to estimate the predicted probability of remaining stroke-free until 
their SHSS exam, conditioned on the same variables (field site, sex, age, prevalent 
diabetes, prevalent cardiovascular disease) as used to estimate the predicted probability of 
selection for stabilized weights in equation 4. Selection weights tailored to the stroke-free 
target population were then estimated as follows: 
 
[6] 
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The tailored weights reduced each person’s influence on the final data analysis in 
proportion to his or her estimated stroke risk, creating a pseudopopulation better aligned 
with inclusion criteria for studying covert VBI. 
Statistical Analysis 
We analyzed the cross-sectional association between hypertension and covert VBI 
using logistic regression models with the binary indicator of WMH score ≥ 3 as the 
outcome. Marginal risk differences were estimated from the fitted logistic models.163 
Mean differences in the continuous measure of white matter volume were estimated using 
linear regression. In both regression models, exposure was the binary indicator of 
prevalent hypertension in the SHSS. 
For the longitudinal analysis, exposure was measured using the multi-category 
variable reflecting each combination of prevalent hypertension status across the all three 
exams (baseline, 10-year follow-up, and SHSS). Because of sparse data for non-
monotonic “recovery” patterns in which people changed from being classified as 
hypertensive at baseline and/or 10-year follow-up to being classified as not having 
hypertension and one or more subsequent exams, we dropped participants in these 
categories (n = 59) from the longitudinal analysis and only considered monotonic 
exposure patterns for which people who were: 1) normotensive at all three exams 
(reference group), 2) normotensive at baseline and 10-year follow-up but hypertensive at 
the SHSS exam, 3) normotensive at baseline and hypertensive at both the 10-year follow-
up and SHSS exams, or 4) were hypertensive at all three exams. For each analysis we 
estimated unweighted crude associations, associations weighted for covariate 
confounding, and associations simultaneously weighted for covariate confounding and 
selection bias. The latter used “master” weights calculated as the product of individual 
weights for confounding and selection.164 Table D.1 summarizes the combination of 
weights for each analysis. Point estimates are reported with 95% confidence intervals. 
We used Stata version 13 (StataCorp, College Station, TX) for all analyses. 
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D.4 Results 
Of the 4549 cohort members who enrolled in the Strong Heart Study from 1988-
1991, 36 had prevalent stroke at baseline and were excluded from this analysis. Of the 
4513 cohort members without prevalent stroke at baseline, 1031 survived and 
participated in the SHSS from 2010-2013. On average SHSS participants were younger, 
better educated, more likely to be female, more likely to be obese, and either healthier 
than or similar to Strong Heart Study cohort members who did not participate (Table 
D.2). In particular, fewer SHSS participants than non-participants had prevalent 
hypertension, diabetes, cardiovascular disease, and albuminuria at baseline.  
Of the 1031 SHSS participants with no stroke at baseline, 934 were also stroke-free 
at the SHSS exam. Before multiple imputation, WMH grade and white matter volume 
were missing for 34 and 59 of these individuals, respectively. After imputation (Table 
D.3), people with abnormal WMH grade tended to be older, have lower educational 
attainment and were less likely to be currently married than people with normal WMH 
grade. Although body mass index on the continuous scale appeared similar between 
groups, people with abnormal WMH had lower prevalence of obesity. People with 
abnormal WMH also tended to have higher prevalence of microalbuminuria, self-
reported myocardial infarction, and self-reported congestive heart failure. As expected, 
people with abnormal WMH grade had more white matter expressed both as total volume 
and as proportion of intracranial volume. Prevalent hypertension at the SHSS exam was 
only slightly more common in people with abnormal WMH. Descriptive statistics for the 
longitudinal hypertension variable was restricted to the subset of 878 participants who 
attended all three study visits (Strong Heart Study baseline and 10-year follow-up, and 
the SHSS). Of these, a lower percentage of people with severe WMH had no 
hypertension or hypertension only at the SHSS, and a higher percentage had hypertension 
at all three study visits.  
Table D.4 shows descriptive statistics for confounding and selection weights by 
hypertension and WMH grade. Among the 934 stroke-free SHSS participants, 81% (n = 
756) had prevalent hypertension and 36% (n = 336) had abnormal WMH grade. Only 56 
(6%) were normotensive and had abnormal WMH. Mean values for stabilized weights 
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centered slightly below 1.0, reflecting the lower average weights for SHSS participants 
vs. non-participants. Weights tailored to the stroke-free population were smaller than 
stabilized weights, with differences approximately proportional to the 91% overall 
probability of remaining stroke free from baseline to the SHSS. 
Approximately one-third of participants without hypertension had abnormal WMH 
grade. Prevalence difference estimates increased after incorporating confounding weights 
regardless of adjustment for differential selection (Table D.5). As expected, point 
estimates also increased in models incorporating selection weights, with similar results 
for stabilized and tailored target populations. In the analysis for the ratio of white matter 
and intracranial volume, covariate adjustment resulted in substantially higher point 
estimates regardless of selection weighting. Selection weighting had little or no impact on 
unadjusted models, but led to approximately 20% higher point estimates in covariate-
adjusted models. 
Table D.6 shows results for the longitudinal analysis comparing prevalence of 
abnormal WMH by the joint distribution of hypertension status at the Strong Heart Study 
baseline and 10-year follow-up exams, and the SHSS exam among cohort members who 
completed all three visits. Due to sparse data for categories in which 59 people with 
hypertension at baseline or 10-year follow-up were classified as normotensive at a 
subsequent visit (Table D.3), these categories were dropped from the analysis (final n = 
819). Having hypertension at all three study visits was consistently associated with higher 
prevalence differences compared to people with no hypertension at any study visit, 
though the magnitude of point estimates decreased in models weighted for time-varying 
confounding. Table D.7 shows results for the longitudinal analysis comparing white 
matter volume as a proportion of intracranial volume. People with hypertension at all 
three study visits consistently showed higher mean values compared to people with no 
hypertension at any visit. In contrast to the binary outcome, magnitude of point estimates 
increased after covariate adjustment. Selection weighting had no apparent impact on 
analyses for the longitudinal analysis. 
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D.5 Discussion 
We found that hypertension correlated with more severe VBI among elderly 
American Indians in the cross-sectional SHSS analysis. In the longitudinal analysis, joint 
patterns of hypertension over 20 years suggested that people with the longest duration of 
hypertension were more likely to have prevalent covert VBI in the SHSS than people 
without hypertension at any exam. After covariate adjustment there was little or no 
difference between people who developed hypertension after the Strong Heart Study 
baseline exam compared to cohort members who remained free of hypertension at all 
visits. These findings are consistent with biological models that view covert VBI as 
arising from cumulative effects of long-term vascular disease,165 and with research in 
other populations.75,77,166-170 Cross-study comparisons are complicated, however, by other 
studies’ reliance on odds ratios for binary outcomes and log-transformation for 
continuous outcomes. We opted for prevalence-based effect measures because prevalence 
is more interpretable than odds and because odds ratios overestimate prevalence ratios 
when outcomes are common,171 as was the case for abnormal WMH. For the continuous 
volume ratio we were interested in overall mean differences at the population level for 
each longitudinal hypertension comparison. These estimates are more easily interpreted 
when adhering to the original scale, and the SHSS sample size was sufficiently large to 
invoke the Central Limit Theorem for unbiased inference.172 In spite of these limitations 
to external comparisons, our results contribute to the growing body of evidence 
supporting a vascular etiology of covert VBI, evidence which is strengthened by the 
similar qualitative conclusions across studies despite variation in design and analytic 
methods. 
In the cross-sectional analysis point estimates increased in models incorporating 
selection weights, as expected if selection bias is affecting SHSS data. In reality the 
assumptions behind IPW models are unlikely to be perfectly satisfied, and so our analysis 
should be interpreted as mitigating, rather than eliminating, selection bias for the cross-
sectional association between hypertension and severe WMH in the SHSS. Contrary to 
our expectations, however, there was no strong evidence that IPW adjusted for selection 
bias in the longitudinal analysis. A possible explanation pertains to the two additional 
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exclusions of participants compared to the cross-sectional models. First, we dropped 
people who did not participate in the 10-year follow-up. Because this subgroup went on 
to enroll in the SHSS, it might comprise disproportionately younger, healthier individuals 
who had temporarily migrated out of the Strong Heart Study communities or who did not 
participate due to work or other obligations as opposed to people who did not participate 
for reasons related to subsequent poor health or mortality. Second, we dropped 59 people 
who had hypertension at the Strong Heart Study baseline and/or 10-year follow-up but 
who did not have hypertension at one or more subsequent exams, and it is highly likely 
this group comprised people with less severe disease and lower risk of hypertension-
related morbidity or mortality compared to their counterparts with monotonic 
hypertension prevalence.  
Tailoring weights to account for inclusion criteria is an important strength of our 
IPW analysis, and departs from conventional applications that stabilize weights to the 
exposure distribution observed in the study cohort. By further tailoring numerators to 
account for stroke risk, we estimated results for a target population aligned with SHSS 
inclusion criteria. This is needed for valid inference because many variables predicting 
higher mortality risk in the selection models (e.g., male sex, higher blood pressure, 
prevalent diabetes and cardiovascular disease) are also well-established risk factors for 
clinical events. Stroke-free SHSS participants with low predicted probabilities of 
selection—and therefore large selection weights—due to the presence of these risk 
factors would simultaneously have high predicted probabilities of clinical stroke. 
Upweighting these individuals without further adjustment could then overcorrect for 
missing observations who would have experienced subsequent stroke. The extent to 
which failing to account for inclusion or exclusion criteria would bias an IPW analysis 
depends on the magnitude of stroke risk in people with high selection weights, and the 
prevalence of stroke in the target population. In our case fewer than 10% of SHSS 
participants had prevalent stroke and it is possible that bias would be less problematic 
than if a more highly prevalent condition were cause for exclusion.  
For investigators who are comfortable estimating stabilized weights, modeling the 
predicted probability of being in a specific target population conditioned on selection and 
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exposure status is a straightforward extension of a familiar method.156 If inclusion criteria 
correlate with selection, it is important to appropriately model their joint distribution 
rather than estimating separate predicted probabilities as if each factor were independent 
of the other(s). The main caveat is that care must be taken to ensure appropriate 
temporality in the conditional model, Pr(Factor1 = f1|Factor2 = f2), if one factor is 
potentially a downstream effect of the other. Flexible specification of the target 
population can facilitate sensitivity analyses, for example by weighting to a population 
that is free of comorbidities or in which no one is taking certain medications. This could 
allow for more nuanced interpretation of effect measure estimates compared to the 
frequent practice of dropping sick or medicated individuals from a data set. 
D.6 Limitations 
Our analysis has limitations that should also be considered when interpreting 
weighted point estimates. First, due to limitations in the SHSS data we adjusted the target 
population based on self-reported prevalent stroke rather than a more rigorous 
adjudicated determination as was available for previous phases of the Strong Heart Study. 
Adjudication for the SHSS is currently underway, however, and it will be a trivial matter 
to adjust the relevant predicted probability estimates once this information is available. 
Furthermore, self-reported stroke has been shown to be a reasonable surrogate for 
adjudicated stroke in other populations.173-178 No publication has specifically compared 
self-reported vs. adjudicated stroke in elderly American Indians, but these studies provide 
some support for the internal validity of our analysis. Second, currently available Strong 
Heart Study data only include adjudicated clinical events and mortality through 
December, 2008. Therefore our prediction models conflate attrition from death and non-
participation of survivors beginning in January, 2009. However, proportionally more 
attrition was due to death as the cohort aged and became less mobile, and SHSS field 
staff have reported that the majority of non-participation was due to excessive frailty or 
other health problems that correlate with mortality. Therefore we are likewise confident 
that selection weights and IPW results will not change dramatically when fully 
adjudicated mortality data become available. Third, we did not use data collected at the 5-
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year follow-up of the Strong Heart Study for estimating time-varying confounding or 
selection weights. Estimates using all available data might be more accurate, but the 
tradeoff is additional complexity and potential for bias to increase exponentially due to 
repeated misspecification of the imputation or prediction models. We therefore 
compromised by estimating weights for two intervals of approximately equal (10 years) 
duration.  
D.7 Summary and Conclusion 
Among elderly American Indians in the SHSS, covert VBI as measured by 
abnormal WMH grade and higher white matter/intracranial volume ratio was correlated 
with prevalent hypertension and with being hypertensive at three study exams conducted 
over 20 years. People with hypertension first detected at the 10-year follow-up or SHSS 
exam did not have substantially worse outcomes than their normotensive peers, 
suggesting a dose-response model with covert VBI developing after long-term exposure 
to hypertension and other vascular diseases. By tailoring selection weights proportional to 
stroke risk in the cohort, our results relate to a target population aligned with SHSS 
inclusion criteria. When variables predicting selection into an analysis also correlate with 
eligibility, investigators might want to consider using tailored weights, especially when a 
large proportion of the study population fails to qualify for inclusion.  
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Table D.1. Weighting scheme for marginal structural models with inverse probability weighting 
 Selection Bias 
Confounding Unweighted Stabilized selection* Tailored selection** 
Crude association: None s_wtfinal t_wtfinal 
Covariate adjusted† cross-
sectional: 
c_wtXS  c_wtXS × s_wtfinal c_wtXS × t_wtfinal 
Covariate adjusted† 
longitudinal: 
c_wtlong c_wtlong × s_wtfinal c_wtlong × t_wtfinal 
* s_wtfinal = stabilized to the predicted probability of selection conditioned on previous 
hypertension status and baseline covariates (field site, sex, age, prevalent diabetes, prevalent 
cardiovascular disease) 
** t_wtfinal = tailored to the predicted probability of being stroke-free in the Strong Heart Stroke 
Study conditioned on selection, baseline hypertension status, and the same baseline covariates as 
for stabilized weights 
† Adjusted for field site, age, sex, baseline education, marital status, body mass index, current 
smoking, current alcohol consumption, high and low density lipoproteins, prevalent diabetes, and 
prevalent cardiovascular disease  
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Table D.2. Strong Heart Study cohort members who did and did not participate in the Strong 
Heart Stroke Study. All variables were measured at baseline exams from 1988-1991; results 
exclude 36 participants with prevalent stroke. 
 Did not participate in SHSS  Participated in SHSS 
 (n = 3482)  (n = 1033) 
 Mean (SD) or %  Mean (SD) or % 
SHS site:    
Southwest 34%  30% 
Southern Plains 34%  34% 
Northern Plains 33%  36% 
Age, years 58 (8)  52 (6) 
Female 57%  69% 
Married 47%  56% 
Education:    
11th grade or less 52%  34% 
High school graduate 25%  29% 
Any post-secondary 23%  37% 
Percent of life spent on a 
reservation 
85 (20)  82 (22) 
Current smoking 34%  34% 
Current alcohol consumption 41%  43% 
Body mass index, kg/m2 31 (6)  31 (6) 
Blood lipids:*    
HDL 46 (14)  46 (13) 
LDL 116 (33)  121 (32) 
Blood pressure:    
Systolic, mmHg 130 (21)  122 (15) 
Diatolic, mmHg 77 (10)  77 (10) 
Prevalent hypertension 43%  26% 
Diagnosed diabetes 54%  33% 
Prevalent cardiovascular disease:    
Myocardial infarction 3%  1% 
Coronary heart disease* 4%  1% 
Congestive heart failure 5%  1% 
Albuminuria:    
None 66%  86% 
Micro (30-299 mg/g) 21%  13% 
Macro (≥ 300 mg/g) 13%  1% 
SHSS = Strong Heart Stroke Study 
* Coronary heart disease includes myocardial infarction 
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Table D.3. Variables collected at the SHSS exam and selected baseline factors for 934 stroke-free 
SHSS participants, stratified by the binary indicator of abnormal white matter hyperintensities. 
 White Matter Hyperintesities 
 Normal: grade 0-2  Abnormal: grade 3-8 
 (n = 598)  (n = 336) 
 Mean (SD) or %  Mean (SD) or % 
SHS site:    
Southwest 31%  30% 
Southern Plains 35%  31% 
Northern Plains 34%  39% 
Age, years 71 (5)  75 (6) 
Female 68%  69% 
Education:*    
11th grade or less 28%  41% 
High school graduate 31%  28% 
Any post-secondary 41%  31% 
Married 37%  26% 
Percent of life spent on a reservation* 81 (23)  83 (21) 
Body mass index, kg/m2 32 (7)  31 (7) 
Obese (BMI ≥ 30 kg/m2) 63%  46% 
Blood lipids:    
HDL 50 (13)  52 (16) 
LDL 98 (35)  91 (32) 
Prevalent diabetes 57%  59% 
Current smoking 19%  18% 
Current alcohol consumption 24%  21% 
Blood pressure:    
Systolic, mmHg 135 (20)  138 (23) 
Diatolic, mmHg 69 (11)  68 (12) 
Prevalent cardiovascular disease:**    
Myocardial infarction 9%  15% 
Congestive heart failure 5%  8% 
Albuminuria:    
Micro (30-299 mg/g) 15%  22% 
Macro (≥ 300 mg/g) 7%  8% 
Brain volume    
White matter, cm3 4.1 (3)  12.1 (8) 
Intracranial, cm3 1204 (128)  1205 (140) 
White matter / Intracranial 0.0033 (0.002)  0.0099 (0.007) 
Cross-sectional exposure    
Prevalent hypertension 80%  83% 
Longitudinal exposure (n = 557)†  (n = 321) † 
No hypertension at any visit 17%  15% 
Hypertensive at SHSS only 36%  32% 
Hypertensive at 10-year follow-up and 
SHSS 
22%  22% 
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Hypertensive at all three visits 17%  26% 
Hypertensive at 10-year follow-up only  2%  2% 
Hypertensive at baseline only  < 1%  < 1% 
Hypertensive at  baseline and 10-year 
follow-up 
< 1%  0% 
Hypertensive at baseline and SHSS only 5%  3% 
* Baseline variable collected by Strong Heart Study (1988-1990) 
** Self-report (adjudication in progress) 
† Only evaluated for participants who attended all three exams 
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Table D.4. Selection weights by hypertension and white matter hyperintensities grade for 934* 
stroke-free Strong Heart Stroke Study participants. 
 No hypertension Hypertension 








 (n = 122) (n = 56) (n = 476) (n = 280) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Confounding 
weights: 
    
Cross-sectional 1.09 (1.4) 0.99 (0.7) 1.00 (0.1) 1.00 (0.2) 
Longitudinal* 0.90 (1.1) 1.03 (0.9) 1.03 (0.5) 1.07 (0.7) 
Selection weights:**     
Stabilized 0.96 (0.2) 0.98 (0.4) 0.96 (0.6) 0.99 (0.5) 
Stabilized and 
tailored 
0.89 (0.2) 0.88 (0.3) 0.88 (0.5) 0.88 (0.5) 
WMH = white matter hyperintensities; SD = standard deviation 
* Longitudinal weights restricted to 878 cohort members who attended all three exams (baseline, 
10-year follow-up, and Strong Heart Stroke Study)  
** Stabilized to overall hypertension distribution and tailored to the stroke-free target population  
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Table D.5. Cross-sectional effect estimates comparing white matter hyperintensity measures in 
people with vs. without prevalent hypertension among 934 stroke-free Strong Heart Stroke Study 
participants. 
 Selection Weighting 
 Unweighted Stabilized 
Stabilized + 
Tailored 
 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Prevalence difference*    
Unadjusted 5.6 (-2, 13) 6.0 (-2, 14) 6.0 (-2, 14) 
Covariate-adjusted† 7.9 (-2, 17) 8.9 (0, 18) 8.9 (0, 18) 
Prevalence ratio*    
Unadjusted 1.2 (0.9, 1.5) 1.2 (0.9, 1.5) 1.2 (0.9, 1.5) 
Covariate-adjusted† 1.3 (0.9, 1.7) 1.3 (0.9, 1.7) 1.3 (0.9, 1.7) 
Mean difference**    
Unadjusted 0.25 (-0.7, 1.2) 0.23 (-0.9, 1.4) 0.24 (-0.9, 1.4) 
Covariate-adjusted† 0.80 (-0.4, 2.0) 0.87 (-0.4, 2.1) 0.87 (-0.3, 2.1) 
Stabilized = overall hypertension distribution; Tailored = stroke-free target population; CI = 
confidence interval 
*  Prevalence of white matter hyperintensity grade ≥ 3 
** Mean difference of white matter volume/intracranial volume, multiplied by 1000 to simplify 
presentation of results 
† Adjusted using inverse probability weighting for confounding by field site, age, sex, education 
at  baseline exam, marital status, body mass index, current smoking and alcohol consumption at 
each exam, high and low density lipoproteins, prevalent diabetes, prevalent cardiovascular 
disease 
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Table D.6. Longitudinal effect estimates comparing prevalence of white matter hyperintensity 
grade ≥ 3 across categories defined by the joint distribution of hypertension at baseline, 10-year 
follow-up, and the SHSS. Reference group for all comparisons is participants who were 
normotensive at all three visits. Analysis was restricted to participants who participated all 
three exams, and 60 participants with “recovery” patterns depicted by gray rows in Table 1 
were dropped from the analysis due to sparse data. Final n = 819. 
 Selection Weighting 
 Unweighted Stabilized Tailored 
WMH grade ≥ 3 Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
Prevalence difference, unadjusted 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS -0.2 (-10, 9) -0.2 (-10, 10) 0.0 (-10, 10) 
Hypertensive at 10 years & SHSS 2.4 (-8, 13) 5.2 (-6, 17) 5.4 (-6, 17) 
Hypertensive at all exams 12.6 (2, 23) 11.6 (0, 23) 11.4 (0, 23) 
Prevalence difference, covariate-adjusted* 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS 0.3 (-13, 14) 0.4 (-12, 13) 0.7 (-11, 13) 
Hypertensive at 10 years & SHSS -2.1 (-16, 12) 0.5 (-13, 14) 0.9 (-12, 14) 
Hypertensive at all exams 8.0 (-6, 22) 7.8 (-6, 22) 8.1 (-6, 22) 
Prevalence ratio, unadjusted 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 
Hypertensive at 10 years & SHSS 1.1 (0.8, 1.4) 1.2 (0.8, 1.5) 1.2 (0.8, 1.5) 
Hypertensive at all exams 1.4 (1.0, 1.8) 1.3 (0.9, 1.7) 1.3 (0.9, 1.7) 
Prevalence ratio, covariate-adjusted* 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 
Hypertensive at 10 years & SHSS 0.9 (0.6, 1.3) 1.0 (0.6, 1.4) 1.0 (0.6, 1.4) 
Hypertensive at all exams 1.2 (0.8, 1.7) 1.2 (0.8, 1.6) 1.2 (0.8, 1.7) 
WMH = white matter hyperintensity; Stabilized = overall hypertension distribution; Tailored = 
stroke-free target population; CI = confidence interval 
*  Adjusted using inverse probability weighting for confounding by field site, age, sex, 
education at  baseline exam, marital status, body mass index, current smoking and alcohol 
consumption at each exam, high and low density lipoproteins, prevalent diabetes, prevalent 
cardiovascular disease 
 
  55 
 
Table D.7. Longitudinal effect estimates comparing white matter volume/total intracranial 
volume across categories defined by the joint distribution of hypertension at baseline, 10-year 
follow-up, and the SHSS. Reference group for all comparisons is participants who were 
normotensive at all three visits. Analysis was restricted to participants who participated all 
three exams, and 60 participants with “recovery” patterns depicted by gray rows in Table 1 
were dropped from the analysis due to sparse data. Final n = 818. Results are presented as ratio 
x 1000. 
 Selection Weighting 









Mean difference, unadjusted 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS 0.07 (-1.0, 1.2)  -0.07 (-1.5, 1.3) -0.05 (-1.4, 1.3) 
Hypertensive at 10 years & 
SHSS 
0.11 (-1.1, 1.3) 0.01 (-1.4, 1.5) 0.04 (-1.4, 1.5) 
Hypertensive at all exams 1.16 (0.0, 2.4) 1.02 (-0.6, 2.6) 1.06 (-0.6, 2.7) 
Mean difference, covariate-adjusted* 
Not hypertensive Ref Ref Ref 
Hypertensive at SHSS 0.68 (-0.7, 2.0) 0.49 (-0.9, 1.9) 0.54 (-0.9, 1.9) 
Hypertensive at 10 years & 
SHSS 
0.30 (-1.0, 1.6) 0.10 (-1.3, 1.5) 0.16 (-1.2, 1.6) 
Hypertensive at all exams 1.69 (0.0, 3.4) 1.57 (-0.2, 3.3) 1.65 (-0.2, 3.4) 
WMH = white matter hyperintensity; Stabilized = overall hypertension distribution; Tailored = 
stroke-free target population; CI = confidence interval 
*  Adjusted using inverse probability weighting for confounding by field site, age, sex, 
education at  baseline exam, marital status, body mass index, current smoking and alcohol 
consumption at each exam, high and low density lipoproteins, prevalent diabetes, prevalent 
cardiovascular disease 
 
  56 
E. Manuscript 3: A bounding method for effect estimates conditioned on age or 
time since exposure 
 
Clemma J. Muller, Alvaro Alonso, David Vock, Jean Forster, Richard F. MacLehose 
 
E.1 Overview 
Background and Purpose. Effect estimates that are calculated separately for 
categories conditioned on age (e.g., 45-54, 55-64, or 65-74 years old) or time since 
exposure (e.g., < 1 year, 1-2 years, and > 2 years after starting treatment) can suffer from 
a type of selection bias which leads to observing effects that are diminished or even 
qualitatively reversed compared to the true effect in the target population. This 
“conditional effects bias” cannot be avoided by study design, nor can it be fixed by 
statistical analysis. We present a method for estimating bounds around the conditional 
risk difference (RD) based on observed data. Formulae are presented for bounds 
assuming that exposure can only have causative effects on the outcome, and allowing for 
the possibility of both preventive and causative effects in the target population. We 
demonstrate the bounding method for analysis of racial differences in post-stroke 
survival. 
Methods. Using population response types and potential outcomes theory, we 
explain conditional effects bias in the context of RD. We used constrained optimization 
to derive bounds around the true conditional RD, first assuming only causal effects 
(monotonicity) and then relaxing monotonicity to allow for the possibility that exposure 
could prevent the outcome in some people while causing it in others. We applied the 
bounds to an analysis of post-stroke mortality in American Indians vs. Blacks and 
Whites. We estimated the RD for three time periods: 0-30 days, 31-180 days, and 181-
365 days after the stroke event. Estimates for the later two periods were conditioned on 
survival to the end of the preceding period. 
Results. Under the assumption of monotonic causal exposure effect, we identified 
bounds around the conditional RD based on observed data. We were unable to identify 
bounds when we allowed for unrestricted magnitude of preventive effects relative to 
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causative effects in the target population. Instead, we identified bounds for the partial 
constraints in which preventive effects were assumed to be equal to or less than causative 
effects. In the example, observed RDs for American Indians vs. Blacks were 14% (95% 
CI = 6, 23) for 0-30 days; -1% (95% CI = -7, 4) for 31-180 days; and -3% (95% CI = -7, 
2) for 181-365 days after stroke onset, respectively. For American Indians vs. Whites, 
analogous observed RDs were 12% (95% CI = -6, 3); 1% (95% CI = -5, 6); and -2% 
(95% CI = -6, 3). Applying the equation for monotonic causal effects for comparisons to 
Blacks yielded bounds of 0%-16% and 0%-13% for 31-180 and 181-365 days after the 
stroke event, respectively. Analogous bounds for comparisons to Whites were 0%-14% 
and 0%-13%. 
Conclusions. Conditional effects suffer from a type of selection bias that can 
compromise the scientific integrity of public health and clinical trials research. We 
describe simple formulae to estimate bounds when conditional comparisons are either 
unavoidable or are of primary interest to investigators. Failure to consider conditional 
effects bias could lead to reporting effects that are attenuated or even reversed across 
categories defined by age or time, when in fact those trends are not conclusively 
supported by the data. 
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E.2 Introduction 
In observational studies and randomized trials, effects are often calculated 
separately for categories defined by participant age (e.g, 45-54, 55-64, and 65-74 years 
old) or time since exposure (e.g., < 1 year, 1-2 years, and > 2 years after initiating 
treatment). In both scenarios the goal is to estimate effects for the age or time period 
represented in each category, conditional on having survived to that age or time period. 
This is accomplished by restricting analyses to the subset of people who have not yet 
experienced the outcome as of the start of the category. Effects conditioned on remaining 
event-free for successively older ages or longer time intervals are widespread in the 
literature and have generated conclusions that are entrenched in public health and clinical 
practice. For example, studies have found that the higher risk of death associated with 
obesity appears to diminish among older people in analyses stratified by age 
category.179,180 This is a conditional effect comparison because subgroups only include 
people who survived to the minimum age for each category, which may be years after a 
person becomes obese. Analyses of racial health disparities frequently condition on age, 
with decreasing magnitudes of effect commonly observed in older groups. In an analysis 
using data from the National Health Interview Survey, hazard ratios comparing mortality 
in Black versus White respondents tended to attenuate among older age categories, 
ranging from 1.3 and 1.5 among women 35-44 and 45-54 years old, respectively, to 0.9 
among women 85 and older.181 Similar patterns were observed in men. 
It is not widely recognized that conditional effect estimates are prone to a type of 
selection bias which can make them unestimable. In one example, observational studies 
repeatedly showed cardiovascular benefits associated with post-menopausal hormone 
replacement therapy,182-185 but a large randomized controlled trial found that hormone 
replacement therapy actually led to increased incidence of coronary heart disease.186 
Conditional effects bias may have contributed to the discrepancy because women in 
observational cohorts typically started using hormone replacement therapy months or 
years before enrolling in the study, whereas women in the randomized trial were under 
observation from the beginning of treatment.187 
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Unfortunately, conditional effects bias cannot be accounted for by study design or 
statistical analysis; even large clinical trials with perfect randomization and no loss to 
follow up are susceptible to the problem.188 If treatment or exposure (used 
interchangeably throughout) causes some people to experience the outcome in earlier age 
categories or time periods than if they had been unexposed, then these more susceptible 
individuals will drop out of the target population but will still be present in the control 
population for subsequent conditional comparisons. This means the control population 
can progress to having higher underlying disease risk than the target population, which in 
turn can lead to observing apparently protective conditional effects even if the exposure 
never prevents disease.6 Although some exposure effects may truly diminish over time, 
conditional effects bias can also obscure the magnitude of change. 
Some authors have advocated avoiding the conditional effects conundrum by 
instead estimating unconditional alternatives such as cumulative effect measures, in 
which comparisons reflect all events occurring since the start of exposure for an age or 
time interval and for which all members of the target population are at risk for the 
outcome. In practice, however, data may not be available to implement this solution or 
the scientific question of interest may require estimating conditional effects. The latter 
scenario, for example, could occur if an insurance company wanted to know whether a 
medication benefit persisted beyond some fixed duration of treatment, or when clinicians 
want to know whether female sex becomes a risk factor for cardiovascular disease after 
some age threshold. In this manuscript we expand on a previous description of 
conditional effects bias6 to derive formulae for estimating bounds around the conditional 
risk difference (RD). Bounds are defined using unconditional risk and RD estimates that 
can be identified from observed data, and generate an interval of possible true RD values. 
We demonstrate the bounds with an applied example.  
E.3 Potential Outcomes, Response Types, and Exchangeability 
Conditional effects bias can be explained using a potential outcomes 
framework.189,190 With a binary exposure and binary outcome, for any given individual 
there is an outcome that would be observed if the person were exposed, and another—
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possibly different—outcome that would be observed if she or he were unexposed. A 
difference between the two potential outcomes reflects a causal effect of exposure for that 
individual. In reality, only one exposure status per person is possible at any given time, 
and only one potential outcome can be observed. The hypothetical outcome for the other 
exposure status is labeled counterfactual. Within this framework, a population can be 
divided into four different groups depending on response to exposure: 1) “doomed” 
people who will experience the outcome regardless of exposure status, 2) “causative” 
people in whom the exposure causes the outcome, 3) “preventive” people in whom the 
exposure prevents the outcome, and 4) “immune” people who will not experience the 
outcome regardless of exposure status. Proportions of each response type in a target 
population can be written as PD (doomed), PC (causative), PP (preventive), and PI 
(immune).191,192 In this population the proportion of people who would experience 
disease if exposed is PD + PC, while the proportion that would experience disease if not 
exposed is PD + PP.  Thus, the RD of exposure is (PD + PC) – (PD + PP) = PC – PP.  
For any given target population, the counterfactual response types that do not 
correspond to actual exposure status must be estimated from a substitute population. We 
will denote the proportions of people with each response type in the substitute population 
as QD, QC, QP, and QI. The substitute population can provide unbiased information to 
estimate a causal effect if we assume it is exchangeable with the target population. 
Exchangeability implies the two groups could have swapped exposure status and we 
would still have observed the same average causal effect. Full exchangeability, meaning 
that all Pj = Qj, satisfies this condition and allows unbiased estimation of causal effects.
193 
Full exchangeability is guaranteed for a randomized trial, but must be assumed in 
observational studies after controlling for confounding.194 In some scenarios weaker 
exchangeability assumptions are also sufficient to estimate unbiased effects.195 
Potential outcomes are more complicated when there are multiple time periods 
during which an outcome could occur. In these scenarios, we want to know whether 
exposure leads to some people getting the disease in earlier or later periods than if they 
had been unexposed. Table E.1 summarizes potential outcomes response types for a 
target population in a study with age or follow up time divided into two periods. For all 
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population proportions Pk,l and Qk,l, subscript k indicates in which period the outcome 
would occur with no exposure, and subscript l indicates in which period the outcome 
would occur with exposure. Omega (Ω) denotes people for whom the outcome does not 
occur during any study period. Thus, there is only one immune response type (PΩ,Ω) 
reflecting people who would not experience the outcome during the study period 
regardless of exposure status. Whether or not these individuals would eventually 
experience the outcome after period 2 is not relevant to estimating the effect of exposure 
during periods 1 and 2. Other response types are subdivided according to when the 
outcome would occur for each exposure condition. Doomed people would experience the 
outcome in the same period regardless of exposure status (P1,1 + P2,2 = PD). Proportions 
for the three causative response types reflect all people for whom exposure causes the 
outcome to occur earlier than if they had instead been unexposed (P2,1 + PΩ,1 + PΩ,2 = PC), 
and similarly for preventive types (P1,2 + P1,Ω + P2, Ω = PP). Analogous proportions in the 
unexposed population that provide substitute information for counterfactual data can be 
denoted by QΩ,Ω, Q1,1, Q2,2, and so on. 
In the sections that follow we explain conditional effects bias and develop bounds 
for the conditional risk difference that can be estimated from observed data. For these 
sections, the exposed group is the target population for all comparisons. We begin by 
assuming causative monotonicity of exposure effect: that exposure cannot prevent the 
outcome for anyone in the target population (PP = 0). For the two-period scenario shown 
in Table E.1, causative monotonicity means that only the first six response types are 
relevant for estimating causal effects. We relax the monotonicity restriction later in this 
manuscript.  
E.4 Unconditional Effects 
Unconditional effects do not require outcome-free survival to any minimum age or 
time since exposure. Cumulative effects are the most common unconditional comparisons 
used in epidemiology and clinical trials research, with comparisons reflecting overall 
disease risk in exposed vs. unexposed groups (because our target population is people 
who were exposed) for some interval beginning at the time when exposure status was 
  62 
initially experienced, chosen, or assigned. Using the population proportions in Table E.1 
and the causative monotonicity assumption, the desired cumulative RD for period 1 is 
(P1,1 + P2,1 + PΩ,1) – (P1,1) = P2,1 + PΩ,1. Because we cannot identify P1,1 from the exposed 
target population, we invoke the exchangeability assumption and substitute the risk in 
period 1 (Q1,1) from the unexposed population to estimate the cumulative RD: 
 [1] 
Note that the individual population proportions P2,1 and PΩ,1 cannot be individually 
estimated. The cumulative RD for period 2 compares the sum of all proportions in the 
exposed target population that experience the outcome in periods 1 or 2 to the sum of all 
proportions that experience the outcome in the unexposed substitute population: 
 [2] 
A less common specification for the unconditional RD focuses on risk within a 
given period for the entire target population, without conditioning on remaining event-
free to the start of the period. Thus all members of the population are represented in the 
risk calculations, but people who already experienced the outcome in a previous period 
are not counted as events. For period 1, the period-specific unconditional RD and 
cumulative RD are identical, and hereafter we use RD1 for these period 1 effects. For 
period 2, the period-specific unconditional RD reflects only population proportions that 
would experience disease in period 2, with substitute information used for the 
counterfactual unexposed condition: 
 [3] 
Although the RD depicted in equation 3 is not frequently reported in public health 
research, it is used in the bounding method described below. The key feature of all 
unconditional risk comparisons is that they can be directly estimated from observed data, 
with the assumption that exchangeability between the target and substitute populations is 
achieved by randomization or covariate adjustment.  
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E.5 Conditional Effects 
Conditional effects are estimated when the RD for period 2 is restricted to people 
who survived event-free to the end of period 1.6,188 Conditional effects could be of 
interest in a randomized trial, for example, if investigators want to know whether 
preventive benefits persist beyond some minimum duration of treatment. Conditional 
effects are also estimated in observational studies that enroll people after they were 
initially exposed, such as a cohort study that enrolls people starting at age 55 but wishes 
to evaluate exposures that began prior to study enrollment.  
Depicting conditional effects using potential outcomes response types requires 
defining the population at risk as people who have not yet experienced the outcome at the 
start of the period. With the notation in Table E.1, the proportion of people in the exposed 
target population who survive past period 1 is PΩ,Ω + P2,2 + PΩ,2. The subgroup of these 
individuals who will experience the outcome in period 2 is P2,2 + PΩ,2, whereas the 
subgroup that would experience the outcome if they had instead been unexposed is P2,2. 




When we rely on the substitute population to provide counterfactual information for 
equation 4, the analogous proportion of people surviving past period 1 is QΩ,Ω + Q2,2 + 
Q2,1 + QΩ,1 + QΩ,2 and the proportion who experience the outcome in period 2 is Q2,2 + 
Q2,1. Therefore, the observed conditional risk difference is: 
 
[5] 
Clearly, the observed conditional RD in equation 5 does not match the desired 
conditional RD from equation 4. Because we cannot isolate Q2,1 from the numerator or 
(Q2,1 + QΩ,1) from the denominator of the substitute population, it is not possible to 
directly estimate the desired RD in equation 4 without imposing additional assumptions. 
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E6 Conditional Effects Bias 
The inequality between equations 4 and 5 arises from fundamental differences in 
who survives past period 1 among the target and substitute populations. The surviving 
exposed subgroup in period 2 is likely to be inherently less susceptible to the outcome 
than the original exposed population, because people with an underlying susceptibility for 
whom exposure caused disease to occur in period 1 (P2,1 + PΩ,1) are no longer considered 
at risk. The desired conditional RD in period 2, therefore, pertains to possible delayed 
exposure effects among these more resilient individuals who were not susceptible to 
exposure in period 1. The surviving unexposed subgroup, on the other hand, still contains 
the people for whom exposure would have caused disease to occur in period 1 (Q2,1 + 
QΩ,1) and who should not be included in the resilient subgroup of interest for estimating 
the conditional RD.  
Conditional effects bias means the desired conditional effect measure cannot be 
estimated from observed data. The unexposed population cannot provide unbiased 
substitute information for the counterfactual data in equation 4 unless we impose 
additional assumptions, such as no exposure effect in period 1 (Q2,1 + QΩ,1 = 0). This 
assumption is also known as a lag effect and may be reasonable for some scenarios, such 
as the multiple years that elapse between asbestos exposure and developing cancer,196 but 
it is not believable for many others. Over long enough time and with ongoing attrition of 
susceptible people from the exposed group, higher underlying disease risk in unexposed 
survivors can lead to observing a diminished or apparently preventive effect of exposure 
in later periods, even when only neutral or causative response types are present in the 
population. Unfortunately, conditional effects bias cannot be avoided even with infinite 
sample size, perfect exchangeability between groups at baseline, and complete follow up 
for the entire population. The problem is that we cannot conclusively distinguish P2,1 
from PΩ,2,
6 and there will always be multiple combinations of response type proportions 
that could explain any observed conditional RD.  
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E.7 Bounding Conditional Effects 
When desired effects cannot be identified, an alternative option is to articulate a 
range of possible true values given the observed data.197 A previous publication 
describing conditional effects bias gave bounds for the unobservable proportion PΩ,2, but 
bounds around response types are not very useful for applied analyses estimating 
conditional effects.6 In this section we describe bounds around the conditional RD for 
period 2, first assuming monotonic exposure effects and only two periods in the study. 
Next we relax the monotonicity assumption, and discuss implications for studies with age 
or follow up time divided into three or more periods.  
We used Wolfram Mathematica software (version 10.3)198 to implement constrained 
optimization for identifying bounds around conditional effects. Mathematica has been 
previously used for bounding effects with uncontrolled confounding, mediation analysis, 
and imperfect treatment compliance,199-207 and can be used to define minimum and 
maximum possible values for the conditional RD, subject to a list of constraints 
expressed as equations (e.g., 0 ≤ x ≤ 1). Mathematica translates these constraints to 
matrix notation that reflects a multi-dimensional space of possible true values for the 
unidentified parameter. Conceptually, Mathematica then uses the simplex algorithm208 to 
“move” along the outer edges of the multi-dimensional shape until it identifies the global 
minimum or maximum value that satisfies all constraints. For the six response types 
present in a population with monotonic causative exposure effects (Table E.1), we 
specified that each population proportion, the sum of all proportions, and the cumulative 
risk difference through period 2 must all lie between [0,1]; RDunconditional,2 between [-1,1]; 
and that RD1 and the conditional surviving exposed population PΩ,Ω + P2,2 + PΩ,2 must be 
greater than 0. The non-zero constraints are necessary because RD1 = 0 implies no 
exposure effect in period 1, and PΩ,Ω + P2,2 + PΩ,2 = 0 implies that no exposed individuals 
survived to the start of period 2. Within these constraints, we the following bounds for 
the conditional RD: 
 
[6] 
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where  is the unconditional risk observed in period 1 for the exposed population. 
Note that equation 6 is also a reformulation of previously described bounds around 
response type PΩ,2.
6 
E.8 Relaxing Monotonicity 
Many exposures can harm some individuals while benefitting others, and conditional 
effects in these contexts can have important public health or clinical relevance. Allowing 
for all preventive and causative response types in Table E.1, the RD for period 1 in the 
exposed target population is RD*1 = (P1,1 + P2,1 + PΩ,1) – (P1,1 + P1,2 + P1,Ω), where the 
asterisk indicates risk estimates allowing for non-monotonic exposure effects. The RD*1 
is the population proportion in which exposure causes disease minus the proportion in 
which exposure prevents disease that would otherwise have occurred in period 1. With an 
exchangeable unexposed substitute population providing the counterfactual data (Q1,1 + 
Q1,2 + Q1,Ω), RD*1 can be estimated without bias. The same is true for the unconditional 
RD* in period 2, written as RD*unconditional,2 = (P2,2 + PΩ,2 + P1,2) – (P2,2 + P2,1 + P2,Ω).  
Allowing for non-monotonic exposure effects adds an additional layer of 
complexity to the conditional RD. If exposure delays some events that would have 
occurred in period 1 (P1,2 + P1,Ω > 0), then the surviving target population in period 2 is 
P2,2 + PΩ,Ω + PΩ,2 + P1,2 + P1,Ω + P2,Ω, and conditional disease risk for this subgroup in 
period 2 is (P2,2 + PΩ,2 + P1,2)/( P2,2 + PΩ,Ω + PΩ,2 + P1,2 + P1,Ω + P2,Ω). The counterfactual 
disease risk in period 2 for this same subgroup if they had instead been unexposed is 
metaphysical, however, because the proportions P1,2 and P1,Ω would have already 
experienced disease in period 1 and therefore would not be included in the counterfactual 
denominator. The same phenomenon prevents defining an appropriate counterfactual 
comparison for estimating the conditional RD with an unexposed target population under 
assumptions of causative monotonicity.6 Instead, defining conditional effects with non-
monotonic exposures requires more restrictive conditions: among the subset of the target 
population who would have survived to the end of period 1 regardless of exposure status, 
what is the effect of exposure in period 2? This restriction conceptually eliminates P1,2 
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The observed conditional RD* in the absence of monotonic exposure effects is defined 
using population response types as:  
 
[8] 
The observed RD* in equation 8 does not pertain to any real-world counterfactual effect 
measure. Furthermore, without monotonicity assumptions it not possible to estimate the 
restricted RD* in equation 7.6,209  
Fortunately, many scientific questions in public health are focused on overall 
outcomes in the target population, with some a priori expectation about directionality of 
the net exposure effect. In these cases it may be sufficient to adopt weaker monotonicity 
assumptions than mutual exclusivity of causation and prevention, by instead assuming 
“marginal monotonicity” of exposure effects at the population level.206 For causative 
marginal monotonicity this means the population proportion of each causative type is 
equal to or greater than the proportion of the preventive type for the same two periods. 
Specifically, causative marginal monotonicity assumes the three inequalities (P2,1 > P1,2), 
(PΩ,1 > P1,Ω), and (PΩ,2 > P2,Ω) are true. With these weaker assumptions, bounds around 
the conditional RD* restricted to the subset of people who would survive past period 1 
regardless of exposure status are defined as follows:  
 
[9] 
where  is the unconditional risk in period 1 observed in the substitute population. 
These bounds are wider than estimates assuming no preventive response types, because 
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the relative magnitudes of causative and preventive response types for  are 
unrestricted within the other linear programming parameters, whereas for the bounds in 
preventive types P1,2 and P1,3 are implicitly set to 0.  
E.9 Three or More Study Periods 
When age or follow up time is divided into more than two periods, the same 
formulae can be used for bounding conditional effects by simply adjusting the definitions 
of periods 1 and 2. “Period 2” will always be the period in which a conditional RD or 
RD* is being estimated, and “period 1” is always the aggregate of all preceding periods. 
This approach is demonstrated in the applied example that follows. 
E.10 Example: Racial Differences in Post-Stroke Mortality 
The Strong Heart Study (SHS) is a prospective cohort study of cardiovascular 
disease and its risk factors in American Indians.1 At baseline exams from 1988-1990 the 
SHS enrolled 4549 participants ages 45-74 years old, representing 13 tribes from three 
geographic regions. A 2004 publication reported higher stroke rates and post-stroke 
mortality for American Indians compared with Blacks and Whites in other cohort 
studies.2 Recently we pooled data from the SHS and the Atherosclerosis Risk in 
Communities Study (ARIC), a large population-based cohort study that enrolled Black 
and White participants from four geographic sites across the US,3 to compare stroke 
incidence and post-stroke mortality for American Indians vs. Blacks and Whites. The 
statistical analysis used logistic regression with marginal standardization to estimate risk 
differences adjusting for sex; age at stroke event; birth year; education; alcohol 
consumption; smoking; and prevalent hypertension, diabetes, and cardiovascular disease. 
We found that American Indians who experienced stroke had substantially higher risk of 
30-day mortality than their Black or White counterparts (Table E.2), but that the 
magnitude of difference attenuated in the analysis of cumulative risk through 1 year after 
stroke onset. One question with clinical and public health relevance is whether the 
smaller RD for cumulative 1-year mortality reflects temporal change in the magnitude or 
direction of racial differences in survival, for example if American Indians experience 
early barriers to receiving acute stroke-related healthcare but have better access to 
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rehabilitation and other long-term services. This question is best answered by estimating 
conditional effects. 
For this example we divided the first year of post-stroke follow up time into three 
periods (0-30 days, 31-180 days, 181-365 days). We estimated the cumulative RD for 
each period, and the conditional RD for 31-180 and 181-365 days after stroke onset. The 
population at risk for each conditional comparison was restricted to the subset of people 
who survived to the end of the preceding period. Cumulative risks were higher for 
American Indians than for Blacks or Whites in all three periods (Table 2), but magnitudes 
of difference decreased over time. Among the subset of people who survived at least 30 
days, there was no apparent difference in survival from 31-180 days after stroke onset. 
Among the subset of people who survived at least 180 days, American Indians appeared 
to have slightly lower mortality than Blacks and Whites.  
We theorized that although American Indian race could confer long-term survival 
benefits for some individuals, considerations such as the disproportionate burdens of 
many stroke risk factors among American Indians, well-documented barriers to accessing 
high quality healthcare, and chronic underfunding of the Indian Health Service—the 
major healthcare source for most Strong Heart Study communities—suggested causative 
marginal monotonicity for post-stroke mortality at the population level. Note that in this 
context causation reflects indirect effects on mortality from the same sociocultural factors 
that gave rise to modern racial categories, such as the stipulation that only enrolled 
members of federally recognized American Indian tribes are allowed to receive care from 
the Indian Health Service. As shown in Table E.2, using equation 6 with assumptions of 
individual-level causative monotonicity led to bounds around the conditional RDs that 
were consistent with long-term differences of similar magnitude as observed for the first 
30 days following a stroke event. Using equation 9 with assumptions of marginal 
causative monotonicity resulted in substantially elevated upper bounds for the true 
conditional RDs, and would require additional user-specified restrictions, such as limiting 
the relative magnitude of causative and preventive response types in , to provide 
meaningful context for interpreting the conditional effect. 
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E.11 Discussion 
Conditional effects suffer from a type of selection bias that can compromise the 
scientific integrity of public health and clinical trials research. Previous publications 
described the problem6,188 and advised estimating alternative effects, such as cumulative 
risk comparisons, that can be identified from observed data. We have described simple 
formulae to estimate bounds for the true effect measure when conditional comparisons 
are either unavoidable or are of primary interest to investigators. As demonstrated in the 
example, failure to consider conditional effects bias could lead to reporting diminishing 
effects or reversal of directionality beyond some threshold in age or time, when in fact 
those trends are not conclusively supported by the data. 
It can be difficult to understand the difference between conditional effects bias and 
other types of selection bias, the latter of which could theoretically be avoided by 
eliminating loss to follow up or other mechanisms for informative missing data. 
Conditional effects bias, in contrast, is a fundamental identification problem that persists 
even with infinite sample size and no missing data. Conditional effects bias cannot be 
fixed by study design or statistical analysis without imposing additional assumptions such 
as no effect of exposure in specific periods. Conditional effects bounds as described here 
can be used by analysts as a sensitivity analysis to contextualize findings. These bounds 
can also be estimated by consumers of published research, when investigators report 
sufficient descriptive information for estimating period-specific conditional and 
unconditional risks. Such information at minimum would comprise unconditional 
denominators for the target and substitute populations, and event counts for each 
population in each age category or time period. With loss to follow-up or attrition for 
reasons other than experiencing the outcome, this information should also be provided to 
allow accurate enumeration of the conditional denominators. 
Data do not always exist to allow estimation of the unconditional risks needed for the 
bounding equations described above. This problem is common in observational data if 
the original target population cannot be enumerated to calculate denominators for 
unconditional risks, or when follow up begins some length of time after exposure and the 
RD cannot be estimated for period 1. For example, in cohort studies that enroll middle-
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aged adults but evaluate exposures predating enrollment, period 1 risks are not directly 
observable and follow up should be viewed as starting in period 2. Bounding conditional 
effects in these scenarios requires substituting external information for the missing 
unconditional risk values. External information can reflect empirical estimates from other 
studies if such data are available, or the investigator’s best guess based on expert 
knowledge. Alternatively, it might be possible to identify values for unconditional effect 
measures that would lead to qualitative reversal of observed conditional risk 
comparisons. Other analytic methods could also be considered, such as Bayesian models 
that specify prior distributions on unobserved parameters. We hope the bounding method 
described here will increase awareness of conditional effects bias and provide a practical 
tool for quantifying its magnitude in applied research.  
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Table E.2. Post-stroke mortality among participants of the Strong Heart Study and 
Atherosclerosis Risk in Communities study. 
 Counts  Observed Risk Difference*  Conditional Effects 
Bounds 
 Deaths At risk  Cumulative Conditional  Monotonic Relaxed 
0-30 days 
AI 64 310       
Black 39 416  14 (6, 23)     
White 71 613  12 (3, 21)     
31-180 days 
AI 21 246       
Black 33 377  11 (2, 20) -1 (-7, 4)  0, 16 0, 35 
White 35 542  11 (1, 20) 1 (-5, 6)  0, 14 0, 31 
181-365 days 
AI 11 225       
Black 18 344  8 (-1, 17) -3 (-7, 2)  0, 13 0, 20 
White 24 507  8 (-1, 17) -2 (-6, 3)  0, 13 0, 33 
* Risk difference comparing American Indians to Blacks and Whites, adjusted for sex, age at 
stroke event, birth year, education, alcohol consumption, smoking, and prevalent disease 
(cardiovascular disease, hypertension, diabetes). 
 
Table E.1. Potential outcomes response types for binary exposure and binary outcome with age 
or follow-up time divided into two periods. 
 Period in which outcome would 
occur… 
Population proportions* 
Response type If not exposed If exposed Target Substitute 
Immune Ω** Ω PΩ,Ω QΩ,Ω 
Doomed 1 1 P1,1 Q1,1 
Doomed 2 2 P2,2 Q2,2 
Causative 2 1 P2,1 Q2,1 
Causative Ω 1 PΩ,1 QΩ,1 
Causative Ω 2 PΩ,2 QΩ,2 
Preventive 1 2 P1,2 Q1,2 
Preventive 1 Ω P1,Ω Q1,Ω 
Preventive 2 Ω P2,Ω Q2,Ω 
* Target population = exposed; Substitute population = unexposed.  
**Ω = Outcome will not occur in either age category or follow-up period 
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F.  Contribution and Future Directions 
This dissertation addressed three issues relevant to evaluating clinical and 
preclinical cerebrovascular disease in American Indians. In Manuscript 1 we found that 
the higher stroke incidence reported in a previous analysis of American Indians in the 
SHS persisted in a direct comparison to White, but not to Black, participants of ARIC. 
After adjusting for risk factors including prevalent hypertension and diabetes, stroke 
incidence in American Indians was only slightly elevated compared to Whites, whereas 
differences increased in magnitude compared to Blacks. Taken together, these findings 
suggest that diabetes-related disparities in American Indians may be important factors for 
understanding stroke disparities in this population, at least compared to Whites from 
communities represented in ARIC. In contrast to results for stroke incidence, our analysis 
not only supported the previous finding of higher 30-day and 1-year post-stroke mortality 
in American Indians, but suggested larger magnitudes of disparities after covariate 
adjustment compared to both Blacks and Whites. Interpretation of these results is limited 
by the fact that Black race in ARIC was highly correlated with residence in the stroke belt 
region of the US, and it is possible that stroke risk in American Indians would be closer 
to risk in Blacks from similar geographic regions.  
This analysis underscores the need for studies of stroke incidence and survival that 
include American Indians in sufficient numbers to allow for more nuanced evaluation of 
interracial stroke disparities across place and time. Unfortunately, the high costs and 
amount of resources needed to enroll cohorts of sufficient size and with long enough 
follow-up to evaluate stroke outcomes are insurmountable barriers to launching new 
studies in today’s funding environment. Instead, existing cohorts can be combined as 
shown here to expand the literature on multi-racial comparisons of stroke and other 
cardiovascular disease events that includes American Indians. Candidate cohorts could 
include the Cardiovascular Health Study (Blacks and Whites from four locations across 
the US),210 the Multi-Ethnic Study of Atherosclerosis (Blacks, Whites, Chinese-
Americans, and Mexican-Americans),211 or the Reasons for Geographic and Racial 
Differences in Stroke Study (Blacks and Whites).212 The Strong Heart Family Study, 
which recruited and examined about 3800 extended family members of 94 index 
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participants from the SHS, is another potential resource for analyzing stroke outcomes in 
AIs once adjudicated events are available with sufficient follow-up time to evaluate 
stroke incidence and fatality. Lastly, smaller hospital-based studies could feasibly be 
designed and funded to better understand post-stroke survival in Native populations, and 
to identify appropriate targets for public health intervention. 
In Manuscript 2 we addressed the need for a standardized protocol to adjust for 
selection bias in the SHSS. Comprising elderly surviving members of the SHS cohort, the 
SHSS is the only large sample of community-dwelling American Indians with brain 
magnetic resonance imaging, cognitive testing, and longitudinal data on risk factors for 
and incidence of cardiovascular disease. The SHSS therefore represents a unique and 
important opportunity to study not only cerebrovascular disease, but also other aging-
related conditions—such as Alzheimer’s Disease—that require access to brain scans and 
data on cognitive function and which have not been adequately studied in American 
Indians. Many analyses using SHSS data will potentially suffer from selection bias due to 
differential survival associated with exposures and outcomes.  
Marginal structural models using IPW are one method of adjusting for selection 
bias, and we propose a protocol that can be used as a guide for uniform application of 
IPW. Importantly, our approach strikes a balance between capitalizing on the breadth and 
depth of longitudinal data collection and minimizing the potential for introducing bias 
from model misspecification. Furthermore, we propose a slight adjustment to 
conventional stabilized weights that ensure appropriate inference to the desired target 
population when inclusion criteria correlate with predicted probabilities of selection. This 
adjustment is relevant not only to SHSS analyses that require excluding participants with 
prevalent stroke, but to other studies whose designs entail a similar combination of 
inclusion criteria and IPW adjustment for selection bias. In our example, stroke 
prevalence was low (< 10%), and it is not surprising that tailoring weights to account for 
stroke risk did not result in substantially different results than obtained by conventional 
stabilization methods. The proposed tailoring method could be more informative, 
however, when inclusion criteria lead to dropping a larger proportion of observations 
from analysis and if observations that are included in the analysis despite low predicted 
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probabilities of selection (and therefore large weights) simultaneously have high 
probability of failing to meet inclusion criteria.  
The relatively minor impact of IPW weighting for selection bias, however, also 
raises considerations about the relative benefit of this method given the time-intensive 
nature of its application. Designing the modeling approach, imputing data, and 
conducting appropriate analyses are not simple nor are they quickly implemented, and 
unless investigators anticipate strong selection bias in their data it could be more 
expedient and sufficiently informative to use other methods for sensitivity analysis. For 
example, spreadsheet-based adjustments in which investigators can specify possible 
magnitudes of differential selection probabilities take far less time and can quickly 
demonstrate approximately what level of selection bias would be necessary to 
qualitatively alter conclusions.213 Ultimately, a tiered protocol in which investigators only 
proceed to the more complicated IPW analysis if simpler methods indicate that such an 
approach is warranted may be preferable. 
In Manuscript 3 we addressed a pervasive identification problem that is not widely 
appreciated by applied researchers. Our goals were to provide an accessible description 
of conditional effects bias, and to present simple bounding formulae that reflect potential 
magnitude of the bias without requiring additional time-consuming or sophisticated 
statistical analyses. One limitation of Manuscript 3 is the problematic nature of bounds 
allowing for non-monotonic exposure effects in the target population. First, simply 
defining a real-world conditional population requires conceptually excluding individuals 
in whom exposure prevents the outcome from occurring in period 1. In a public health 
setting where overall average effects are of interest, this contortion may still yield 
meaningful results. Because it is impossible to conclusively identify which individuals 
would be excluded from the surviving target population, however, the constrained 
definition would not yield effect estimates that could readily be applied to any given 
individual in a clinical setting. Additional research or analysis would be required to 
predict a given person’s likelihood of being among the population proportions 
corresponding to preventive response types. Second, even if one accepts the conditional 
target population as presented, requiring no restrictions in relative magnitude of 
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preventive vs. causative response types beyond marginal monotonicity resulted in bounds 
that were too wide for useful interpretation. Future research could focus on narrowing 
bounds by directly inputting observed risk data into optimization algorithms, or by 
identifying bounds for a menu of additional user-specified constraints based on subject 
matter knowledge. Presenting a range of subjective, but minimally restrictive, constraints 
could facilitate more meaningful sensitivity analysis without requiring the assumption of 
individual-level monotonicity.  
Another important limitation of Paper 3 is that it only presents formulae for 
bounding RD comparisons on the absolute scale, whereas bounds are not provided for the 
more ubiquitous multiplicative effect measure of relative risk. This choice was partly 
driven by our inability to derive bounds for the relative risk that allow for non-monotonic 
exposure effects in the target population without requiring additional assumptions that are 
not necessarily supported by the data. Future research should explore the use of weak 
assumptions that allow derivation of bounds for the relative risk, for example specifying 
an upper limit that exceeds any value which would reasonably be expected in clinical 
trials or public health research (e.g., less than 10-fold difference). With this approach the 
challenge may be to find a balance between assumptions that aren’t too restrictive but 
still yield bounds are narrow enough to provide a useful estimate of potential conditional 
effects bias. Similarly, future research could focus on Bayesian methods that specify 
weak prior distributions around unidentified parameters and allow for evaluation of 
conditional effects bias under a range of transparent specifications. 
Taken together, these three papers contribute to the scant public health literature on 
stroke and cerebrovascular disease in American Indians, and more generally to the 
methodological toolbox for unbiased identification of effect measures in which estimates 
are conditioned on survival to some threshold defined by age or time since exposure. We 
hope this work will be accessible to applied researchers working to understand and 
remediate public health disparities defined by race and in other underserved populations. 
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G.  APPENDIX 
 
Hazard ratios for all covariates in the fully adjusted Cox regression model of incident 
stroke by race and birth cohort tertile. 

















Race:      
American Indians vs. Blacks 0.79 (0.61, 1.01)  0.73 (0.54, 0.98)  0.60 (0.44, 0.84) 
American Indians vs. Whites 1.14 (0.90, 1.45)  1.15 (0.85, 1.55)  1.08 (0.76, 1.53) 
Birth year 1.00 (0.97, 1.03)  0.99 (0.94, 1.04)  0.99 (0.93, 1.06) 
Female 0.80 (0.68, 0.94)  0.79 (0.64, 0.97)  0.85 (0.67, 1.08) 
Education (ordinal categories) 0.98 (0.88, 1.09)  0.78 (0.68, 0.90)  0.73 (0.62, 0.87) 
Current alcohol consumption 0.92 (0.78, 1.10)  0.86 (0.69, 1.06)  0.90 (0.70, 1.15) 
Current smoking 1.76 (1.47, 2.10)  1.99 (1.61, 2.45)  2.01 (1.58, 2.57) 
Body mass index 1.00 (0.98, 1.01)  0.99 (0.97, 1.01)  1.01 (0.99, 1.03) 
Congestive heart failure 1.37 (1.01, 1.85)  1.13 (0.75, 1.70)  1.34 (0.81, 2.22) 
Coronary heart disease 1.54 (1.15, 2.05)  2.27 (1.57, 3.27)  1.84 (0.99, 3.42) 
Hypertension* 1.30 (1.14, 1.47)  1.29 (1.11, 1.49)  1.33 (1.11, 1.60) 
Blood pressure ≥ 140/90 
mmHg at baseline 
1.30 (1.07, 1.58)  1.35 (1.04, 1.74)  1.61 (1.17, 2.20) 
Diabetes** 1.19 (0.98, 1.44)  1.13 (0.87, 1.47)  1.39 (1.01, 1.90) 
Fasting glucose ≥ 126 mg/dL 
at baseline 
1.27 (0.87, 1.85)  2.01 (1.20, 3.35)  1.63 (0.89, 2.96) 
CI = Confidence interval 
* Ordinal categories (normal, borderline, hypertensive) 
** Ordinal categories (none, impaired fasting glucose, diabetic) 
 
 
 
